Last Updated: September 9, 2026 TL;DR: Mauritius answers the question we ask of every market — does it name the authorities it will lean on, and is India's CDSCO among them — with a list of the wrong noun. There is no published list of foreign regulatory agencies, but there is a statutory list of PHARMACOPOEIAS, and the Indian Pharmacopoeia is on it by name, in the Pharmacy Act itself. That is recognition of a book of standards, not of an agency, and it opens no fast track. The route that does exist runs through a licensed Mauritian wholesale pharmacy, on certificates that expire every year. Key Takeaways The Indian Pharmacopoeia is named in primary legislation. Section 50 of the Finance (Miscellaneous Provisions) Act 2020 amended the definition of "specified standards" in section 2 of the Pharmacy Act 1983, so it now reads British, French, United States, European or Indian Pharmacopoeia, with effect deemed from 1 January 2019. It is not recognition of CDSCO, it creates no abridged or reliance pathway, and it does not waive registration. The manufacturer keeps the registration, but cannot file alone. The Competition Commission of Mauritius's 2021 market study records that the manufacturer is the applicant and becomes the owner of registration — unusually favourable to an exporter — while having to assign one licensed wholesale pharmacy as its legal technical representative, which carries pharmacovigilance responsibility to the Board. Only licensed Mauritian wholesale pharmacies may import. Registration is not a purely technical assessment, and it expires annually. The same study reports that alongside quality, safety and efficacy the Board weighs PRICE and the number of comparable products already on the market — an additional generic can be refused because enough similar products exist. A certificate of registration is valid for one year, renewable annually under section 25(6). Two harder facts, stated not buried. A reported but unpublished criterion looks for licensing in Pharmaceutical Inspection Convention countries for an undefined subset of "highly critical" drugs, and neither Mauritius nor India is a PIC/S Participating Authority. Published fees and timelines conflict across government sources, so we print neither. Introduction: Why Mauritius Demands a Premium Injectable Manufacturer in Mauritius Every market in this series opens with the same question: does the country publish a list of foreign regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Mauritius returns a new answer. It publishes no list of foreign agencies at all — we searched and found none, and found no reliance route keyed to CDSCO or to anyone else. What it publishes instead, in the Pharmacy Act 1983, is a list of a different noun: pharmacopoeias. Since section 50 of the Finance (Miscellaneous Provisions) Act 2020, deemed in force from 1 January 2019, "specified standards" means the British, French, United States, European or Indian Pharmacopoeia. Read that precisely; over-reading it is the main hazard in this market. A product built to an Indian Pharmacopoeia monograph meets a live statutory quality gate: section 24 prohibits selling a pharmaceutical product that does not conform to specified standards, and section 31(1) applies the same test to Sixth-Schedule therapeutic substances. It does not waive registration under section 25, creates no fast track, and says nothing about GMP or site inspection. A serious injectable manufacturer in Mauritius uses it for what it is — a real advantage on specifications, and nothing more. What Sets a World-Class Injectable Manufacturer in Mauritius Apart Factory rules and buyer rules are different rules, and in Mauritius the binding one sits on the buyer. Part VII of the Pharmacy Act licenses factories in Mauritius: "manufacturer" is defined as a person licensed under section 36, and section 36(5) requires adequate facilities for sterile preparations and suitably experienced supervision. A Gujarat plant is not a "manufacturer" within the meaning of that Act. The overseas route is product registration under section 25, made through a licensed wholesale pharmacy established in Mauritius — under section 23 such a wholesaler needs a licence and a full-time pharmacist in charge, and only licensed wholesale pharmacies may import. What sits above that is unusually good news for an exporter, and easy to get backwards. On the Competition Commission's account, the manufacturer is the applicant and becomes the owner of registration; the Mauritian wholesaler is assigned as legal technical representative and carries pharmacovigilance responsibility to the Board, and authorised distributors are named separately. The Ministry's own published approved-product list corroborates the design: it carries the local representative and the marketing authorisation holder in separate columns, and numerous Indian companies appear as holder. Registration is not owned by the local agent. Quality Systems Behind Every Injectable Supplied to Mauritius The registration file is described as being in Common Technical Document format — CTD, and we found no published Mauritius requirement for eCTD or ACTD, so we claim neither. As described in the Competition Commission of Mauritius's 2021 market study, it normally carries the country-of-origin authorisation, the manufacturer's WHO-GMP certification, a Certificate of Analysis and a Certificate of Pharmaceutical Product, full composition with raw-material sourcing, quality and stability data, price information, and two samples. Frame each of those as what the study describes, not as what the Board currently requires: we did not find the Board's guidelines published anywhere, and the Commission reported in 2021 that it was unclear whether they are publicly available at all. For a sterile injectable the technical work is ordinary aseptic discipline — process simulation for the ISO Class 5 filling line, environmental monitoring, container-closure integrity, sterility and bacterial endotoxin testing by LAL, and validated HPLC and GC methods — carried out knowing that the Board does not systematically submit samples for testing at registration, so the paper file does the work. On stability, we found no published Mauritius-specific climatic-zone designation; the data appear among dossier contents with no stated condition, and exporters should confirm the long-term condition with the Board. Mauritius does not appear on WHO's August 2026 ML3/ML4 list, and CDSCO's own ML3 listing carries the scope "Vaccines (producing)" only. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Mauritius for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Mauritius we build the dossier in CTD structure, supply the WHO-format certificate of a pharmaceutical product and the WHO-GMP certificate, and specify to Indian Pharmacopoeia monographs where that is the appropriate standard — which Mauritius law names directly. Because the file must be lodged through a licensed Mauritian wholesale pharmacy that will also act as legal technical representative, the route begins with a named local partner. We have verified none and recommend none. Two constraints belong in an honest offer. The first is the market test: registration can be refused on price, or because the Board considers there are already enough similar products with no advantage in price or pharmacological action. The second is the reported PIC criterion — a Mauritian competition-authority study reported that for certain drugs, "in particular, highly critical drugs", the Board looks for licensing in Pharmaceutical Inspection Convention countries. We found no published instrument containing it and its scope is undefined, but it cuts against an Indian-origin file, because India is not a PIC/S Participating Authority. Mauritius is not one either, and appears among the observer countries on ZaZiBoNa's published membership page. Every figure here carries its basis. The US Commercial Service's Mauritius Country Commercial Guide, published February 2026, puts India at 39% of the market as of 2024 — that figure is unsourced on its page, so we attribute rather than assert it. The Ministry of Health and Wellness states that its pharmaceutical procurement section deals mainly with purchases above MUR 1.2 billion annually, by open international bidding on annual requirements. Population is about 1.24 million on Statistics Mauritius's end-2025 estimate, against 1.27 million on WHO's profile for 2023 on a UN basis. Current health expenditure was 5.6% of GDP in 2023, roughly 45% of it paid out of pocket — which is what makes the price criterion bite. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Does Mauritius recognise India's CDSCO? We found no published list of recognised foreign regulators for Mauritius, and no reliance route keyed to CDSCO. What Mauritius does publish, in the Pharmacy Act itself, is a list of accepted pharmacopoeias — and the Indian Pharmacopoeia is on it, added by section 50 of the Finance (Miscellaneous Provisions) Act 2020 with effect deemed from 1 January 2019. That is recognition of a book of standards, not of an agency's decisions, and creates no abridged pathway. WHO lists CDSCO at maturity level 3 with the scope "Vaccines (producing)" only. Who registers medicines in Mauritius, and how long does a registration last? The Pharmacy Board, established under the Pharmacy Act 1983 and sitting under the Ministry of Health and Wellness, advised on applications by the Trade and Therapeutics Committee. Do not confuse it with the Pharmacy Council of Mauritius, which registers pharmacists rather than medicines. Under section 25(6) a certificate of registration is valid for one year from its date and may be renewed annually — not five years, as in most markets. Can an Indian manufacturer apply to the Pharmacy Board directly? No. Applications are made through a licensed wholesale pharmacy established in Mauritius, and only such licensed wholesalers may import. The manufacturer is nevertheless the applicant and becomes the owner of the registration, on the Competition Commission's 2021 account; it must assign one wholesale pharmacy as its legal technical representative, which represents it before the Board and carries pharmacovigilance responsibility. The Pharmacy Act's manufacturing-licence regime applies to plants in Mauritius and is not a route for an overseas site. What does it cost and how long does it take? We are not going to print either figure, because the published sources conflict. Fees are prescribed by the Pharmaceutical Product (Fees) Regulations 2016, and government sources differ materially. On timelines, published estimates run from about one month to under six months and we could not reconcile them. Confirm both directly with the Board. Beyond registration, each consignment needs a clearance issued by the Registrar through TradeNet, and Sixth-Schedule therapeutic substances — which since 2021 sweep in antibiotics and biological products approved by the Board — need a per-consignment permit. What can Farbe Firma actually do for a buyer in Mauritius? Manufacture, and prepare the file. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. We build dossiers in CTD and ACTD structure, provide the WHO-format CPP and GMP certificate, and generate stability and aseptic process simulation data. We hold no Mauritian registration and make no claim to one; the route runs through a licensed Mauritian wholesale pharmacy acting as legal technical representative. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 6, 2026 TL;DR: Cyprus is an EU member state, and that makes it a different animal from every market this series has covered. The question is not whether India is on a reference list — there is no such list to be on. It is who holds the marketing authorisation and who certifies the site. The EU's published mutual recognition partners for GMP are Australia, Canada, Israel, Japan, New Zealand, Switzerland and the United States; India is not among them. Article 8(2) of Directive 2001/83/EC, in the consolidated text as at 1 January 2025, provides that a marketing authorisation may only be granted to an applicant established in the Community. Key Takeaways We found no reliance route, and nothing we read in the trade agreement creates one. The EU's published MRA partners on GMP are Australia, Canada, Israel, Japan, New Zealand, Switzerland and the United States. India does not appear on the European Commission's list of third countries assessed as having an equivalent framework for active substances. The EU and India concluded free-trade negotiations on 27 January 2026, and the Commission's published chapter-by-chapter summary shows no chapter or annex providing for mutual recognition of GMP inspections. Two regulatory objects, not one. The marketing authorisation licenses a product, in a form and strength; in Cyprus it is granted by the Drugs Council on the Pharmaceutical Services' assessment, on a CTD dossier filed in eCTD. The manufacturing authorisation licenses a named legal person to make or import named products at named premises, is granted after inspection, and requires a qualified person permanently and continuously. A site outside the EEA receives instead an EU GMP certificate, recorded in EudraGMDP. Importing means an EU authorisation, a Qualified Person and, for India, importation testing. The Pharmaceutical Services' own page states that the manufacturing authorisation is also required for imports of medicinal products originating in third countries. Under Article 51(2) of Directive 2001/83/EC a qualified person is relieved of importation controls only where they were carried out in a third country with which the EU has an MRA — and no EU–India MRA exists. A small, price-disciplined market with a manufacturing base of its own. Cyprus sets maximum wholesale prices by external reference pricing against a basket of ten European countries, with the first generic entering at 80% of the originator's maximum wholesale price. Retail pharmaceutical spending was 467 euro per capita (PPP-adjusted) in 2023 against an EU average of 510. Introduction: Why Cyprus Demands a Premium Injectable Manufacturer in Cyprus Every market in this series opens with the same question — does the country name the regulators it will lean on, and is India's CDSCO among them — and Cyprus is the first where the question itself has to be rewritten. Cyprus is an EU member state. Medicines are authorised under Directive 2001/83/EC and Regulation (EC) No 726/2004, and there is no national reference list on which an Indian approval might or might not appear. What exists instead is structural, and is better described by two questions: who holds the marketing authorisation, and who certifies the manufacturing site? On the first, Article 8(2) of the Directive, which we read in the consolidated text as at 1 January 2025, provides that a marketing authorisation may only be granted to an applicant established in the Community. On the second, the EU's published mutual recognition partners for GMP are Australia, Canada, Israel, Japan, New Zealand, Switzerland and the United States; India is not among them, and India does not appear on the Commission's list of third countries with an equivalent framework for active substances; CDSCO still issues the written confirmations for active substances that only unlisted countries need to issue. No shortcut is arriving: the EU and India concluded free-trade negotiations on 27 January 2026, and the Commission's published chapter-by-chapter summary shows no chapter or annex providing for mutual recognition of GMP inspections. A serious injectable manufacturer in Cyprus says all of that out loud. What Sets a World-Class Injectable Manufacturer in Cyprus Apart The cleanest primary evidence here is the Pharmaceutical Services' own page on manufacturing and import authorisations. Under Cypriot law, manufacture of medicinal products and operations of dividing up, packaging and presentation are permitted only under an authorisation granted by the Drugs Council — and the same page states that the authorisation is also required for imports of medicinal products originating in third countries into the Republic. It is granted only after inspection, requires at least one qualified person on a permanent and continuous basis, is issued within 90 days of a complete file, and runs five years. Somebody in the EEA must hold that authorisation, and that somebody cannot be an entity located in India. Separating the site regime from the product regime is what makes an honest offer possible. A WHO-GMP certificate issued by an Indian state licensing authority is evidence about a site. It is not a marketing authorisation, and it is not an EU GMP certificate: the EU runs its own GMP guide, inspections and certification, and absent an MRA it does not treat WHO-GMP as a substitute. EU GMP certificates for third-country sites are issued following inspection by an EEA competent authority and recorded in EudraGMDP; we could not query that database successfully and make no claim about which Indian sites appear in it. Quality Systems Behind Every Injectable Supplied to Cyprus For a sterile injectable entering the EU the technical expectations are the EudraLex ones, and they are met at the line rather than in correspondence: aseptic process simulation for the ISO Class 5 filling operation, environmental monitoring with trended data, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, and validated HPLC and GC methods for assay and related substances. Module 3 of the CTD carries all of it, and Cyprus files in eCTD. One further capability is worth building before it is asked for — serialisation: Delegated Regulation (EU) 2016/161 has applied since 9 February 2019 and requires a unique identifier and an anti-tampering device on the outer packaging, verified through the national system operated in Cyprus by KOEF, while the obligation to upload the identifier data sits with the authorisation holder. One legislative caution: Parliament and Council reached political agreement on reforming EU pharmaceutical legislation on 11 December 2025, but as of writing we have not verified formal adoption or Official Journal publication, and Directive 2001/83/EC and Regulation (EC) No 726/2004 remain the operative instruments. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Cyprus for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Cyprus the offer is deliberately narrower than the title of this article suggests: we are a contract manufacturer for partners who hold, or intend to hold, an EU marketing authorisation. The site is capable — WHO-GMP certified, and EU-GMP certified if and when an EEA competent authority inspects and certifies it. The product is authorised by someone else, and the batches are certified by someone else, because no MRA waiver applies to goods made in India. What that leaves out matters as much as what it includes. We hold no Cypriot or EU marketing authorisation, we are not established in the EU, and no CDSCO approval advances a European application. We found no India–Cyprus health or pharmaceutical memorandum, which is not the same as saying none exists. India–Cyprus bilateral trade was approximately USD 140 million in 2024–25; we do not publish a disaggregated pharmaceutical figure, because the one we found came from a reseller we could not corroborate. On procurement, the well-documented architecture is the pre-2019 one recorded by PPRI: central tendering, open invitations for off-patent products and negotiation for on-patent ones, with tenders above 133,000 euro published in the EU's Tenders Electronic Daily. GESY changed that architecture, and current arrangements should be confirmed with the Pharmaceutical Services and the Health Insurance Organisation rather than assumed. Our own count of pharmaceutical notices on Tenders Electronic Daily with Cyprus as the place of performance, retrieved on 6 September 2026, is approximately 3,085 — notice counts, not contract counts, and ours rather than official statistics. Population figures must carry their basis: about 966,365 on Eurostat's 2024 figure for the areas under the effective control of the Republic, against whole-island estimates of roughly 1.3 million. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Does Cyprus or the EU accept Indian CDSCO approvals? No. Cyprus authorises medicines under EU law, and a CDSCO approval has no standing in a Cypriot or EU marketing authorisation procedure. The EU's published mutual recognition partners for GMP are Australia, Canada, Israel, Japan, New Zealand, Switzerland and the United States; India is not among them, and India does not appear on the Commission's list of third countries with an equivalent framework for active substances. India's WHO maturity level 3 listing carries the scope 'Vaccines (producing)'. Can an Indian company hold a marketing authorisation in Cyprus? Article 8(2) of Directive 2001/83/EC, in the consolidated text as at 1 January 2025, provides that a marketing authorisation may only be granted to an applicant established in the Community. In practice an Indian manufacturer works through an EU-established partner who holds the authorisation and names the Indian site in Module 3. A derogation inserted by Directive (EU) 2022/642 let Cyprus, Ireland and Malta grant certain authorisations to applicants established in parts of the United Kingdom outside Northern Ireland until 31 December 2024; those cease to be valid at the latest on 31 December 2026. Is WHO-GMP certification enough to supply Cyprus? No. WHO-GMP certification is evidence about a site, and useful evidence, but EU supply additionally requires EU GMP compliance verified by an inspection carried out by an EEA competent authority, recorded in EudraGMDP, and a marketing authorisation held by an EU-established holder. Because there is no EU–India mutual recognition agreement, the Article 51(2) waiver from importation controls does not apply, so importation testing is performed on each batch in the EU. How are medicines priced and bought in Cyprus? Maximum wholesale prices are set by external reference pricing against ten countries — Germany, Denmark and Austria in the high group, Italy, Belgium, Sweden and Spain in the medium, Greece, Portugal and France in the low — averaging the lowest of the high group, the two lowest of the medium and the lowest of the low, plus 3% for import cost, with the first generic at 80% of the originator. PPRI records central tendering, with larger tenders published in Tenders Electronic Daily. What can Farbe Firma actually do for a partner supplying Cyprus? Manufacture. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For an EU-facing partner we prepare CTD Module 3 quality documentation to EudraLex expectations, run ICH Q1A and Q1B stability, provide aseptic process simulation, container-closure integrity, sterility and LAL endotoxin data, and apply serialised 2D DataMatrix coding to Delegated Regulation 2016/161. We also prepare ACTD files for Asian markets. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 6, 2026 TL;DR: Timor-Leste answers the question we ask of every market — does it name the regulators it will lean on, and is India's CDSCO among them — with a named list on which CDSCO does not appear. The list is a route switch, not a bar: question E1 of the DNFM's registration form names ten agencies plus WHO prequalification, yes sends the file to Route A and no sends it to Route B, and both branches end in a registration number. Two harder facts frame it: the statutory basis is in transition, and the applicant must be an importer seated in the country. Key Takeaways A named list, and CDSCO is not on it — but WHO prequalification is. Question E1 of the DNFM importer application form of January 2024 names Indonesia's BPOM, Singapore's HSA, Thailand's FDA, Malaysia's NPRA, the TGA, the EMA, Health Canada, Swissmedic, Japan's PMDA and the US FDA, plus WHO prequalification. CDSCO is absent there, and from the 2018 form and 2023 checklist. WHO's August 2026 list records CDSCO at maturity level 3 with the scope 'Vaccines (producing)' only. Route B is a documentation route, not a refusal: a GMP certificate for the finished-product site issued no longer than two years ago, a valid CPP for export to Timor-Leste — free-sale certificates are not accepted in its place — a batch certificate of analysis, the list of countries where the product is approved, three-batch stability with the climate zone declared, a full ASEAN Common Technical Dossier on USB, and a sample. The DAIM procedure sets a 30-day target and 90-day maximum. The legal basis is in transition and should be said plainly. Decree-Law 12/2004 was repealed in full by Article 77 of Decree-Law 2/2025, in force from 23 January 2025, although the DNFM's forms still cite it. Article 56(2) cross-refers to a marketing-authorisation decree-law that we searched for in the Jornal da República for 2025 and 2026 and did not find published. You cannot be the applicant, and the money is at INFPM. Article 44(a) of Decree-Law 2/2025 requires the authorisation-holder to be seated in national territory and Article 44(d) requires a pharmacist as technical director. SAMES was succeeded by the Instituto Nacional de Farmácia e Produtos Médicos under Decree-Law 57/2023, which publishes tenders and awards; our own approximate count of its published medicine awards is twelve lines worth about USD 2.01 million. Introduction: Why Timor-Leste Demands a Premium Injectable Manufacturer in Timor-Leste Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Timor-Leste answers it in one line on a form. Question E1 of the DNFM importer medicine application form, version 2.1 of January 2024, asks whether the product is approved by one of ten named agencies — among them Indonesia's BPOM, Singapore's HSA, the TGA, the EMA and the US FDA — or is WHO-prequalified. Yes sends the file to Route A; no sends it to Route B. CDSCO is not among them, and it is absent from the 2018 form and the September 2023 checklist too. That absence is not exclusion. Nothing we read says a product from an unlisted country is refused, and the registration numbering scheme — AIMTL, year, route letter, sequence — shows Route B files end in registrations. A published DNFM FAQ states the intent plainly: future requirements will streamline registration for medicines authorised by trusted regulatory bodies, while additional data is needed for others. So the answer costs paperwork rather than access, and a serious injectable manufacturer in Timor-Leste plans for it. One caution: the 2018 form, the 2023 checklist and the 2024 forms remain published simultaneously with overlapping but not identical country sets, and we could not establish which is currently operative. What Sets a World-Class Injectable Manufacturer in Timor-Leste Apart The rules about your factory and the rules about your buyer's licence are different rules, and here the binding one sits on the buyer. On the factory side the requirements are demanding but not origin-restricted: the GMP certificate must be current within two years and no instrument we read says which authority must issue it, and the 2018 form warns that a manufacturing licence is not the same thing as a GMP certificate. On the local side, Article 44(a) of Decree-Law 2/2025 requires the authorisation-holder to be seated in national territory, Article 44(d) requires a permanent and exclusive pharmacist as technical director, and Article 51 requires climate-controlled distribution. The transition in the statute is the fact most easily glossed. Decree-Law 12/2004 was repealed in full by Article 77 of Decree-Law 2/2025 of 22 January 2025, and the DNFM's published forms still cite it as their legal basis. Article 56(2) of the new decree-law cross-refers to a separate decree-law on marketing authorisation; we searched the Jornal da República Série I for 2025 and 2026 and did not find it published. Diploma Ministerial 10/2004 sets the registration fee at USD 100 per medicine per form and dosage, though whether that schedule survives the repeal of its parent decree-law is unconfirmed. We searched in English, Portuguese and Tetum and found no body called ANMAS. Quality Systems Behind Every Injectable Supplied to Timor-Leste For a sterile injectable the technical file is where a Route B application is won, because no national laboratory stands behind it — the April 2025 policy records that there is currently no laboratory testing of medical products through national laboratories, while a physical sample still travels with the file. Expect aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, and validated HPLC and GC methods for assay and impurities. On stability the instruments differ and both readings should be reported: the September 2023 checklist specifies three batches in Zone IVb, 30°C and 75% relative humidity, while the 2024 forms let the applicant declare Zone IVa, Zone IVb or other, and a published FAQ warns that a shorter shelf life may be applied where Zone IVb data cannot be provided. Shelf lives under 24 months are generally not acceptable, with exceptions. The bioequivalence rationale is scoped to oral solids and does not bite on injections. Neither Timor-Leste nor India appears on the PIC/S list of 54 participating authorities. Labelling must be in Tetum and Portuguese, or provisionally Indonesian or English. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Timor-Leste for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, positioning itself to serve Timor-Leste through a locally licensed importer. We build dossiers in CTD and ACTD format, which is the structure Route B asks for, and supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course. Because the applicant must be based in Timor-Leste with an import licence and a pharmacist to sign, the route begins with a named local partner. Candidates are visible in the public record, but we have verified none and recommend none. The bilateral relationship is young and its pharmaceutical content is thin but real. India announced a resident mission in Dili on 7 September 2023 and established the embassy on 5 September 2024. The two countries signed a memorandum on cooperation in healthcare on 7 April 2018, which expired in April 2023 and has been renewed for five years; it is a cooperation instrument, and we found nothing in it touching medicine registration, pharmacopoeial recognition or regulatory reliance. The Embassy of India in Dili reports total bilateral trade of USD 52.20 million in 2025–26; we could not locate a disaggregated pharmaceutical figure. Where the money is, with every figure carrying its basis. Population is roughly 1.4 million: the World Bank estimate is 1,400,638 for 2024, while the 2022 census recorded 1,341,737 usual residents. Current health expenditure was 9.60% of GDP in 2023, up from 7.46% in 2022, but spending per person fell from USD 174.92 to USD 144.21 because GDP contracted — the share rose and the spending did not. Out-of-pocket payments were 6.99% of current health expenditure in 2023. Our own approximate count of INFPM's published medicine awards on 6 September 2026 is twelve lines totalling about USD 2.01 million, and a specialist-medicines tender with a USD 530,000 budget was open, closing 14 September 2026. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Timor-Leste's list of recognised regulatory authorities? No. Question E1 of the DNFM importer application form of January 2024 names ten agencies plus WHO prequalification, and India's CDSCO is absent, as it is from the 2018 form and the 2023 checklist. Absence is not exclusion: E1 selects Route A or Route B, and both end in a registration number. WHO's August 2026 list records CDSCO at maturity level 3 for vaccines only. What law governs medicine registration in Timor-Leste? The position is in transition. Decree-Law 12/2004 was repealed in full by Article 77 of Decree-Law 2/2025 of 22 January 2025, although the DNFM's published forms still cite it. Decree-Law 2/2025 regulates the licensing of import, storage, distribution, sale and export, and its Article 56(2) cross-refers to a separate decree-law on marketing authorisation that we searched for and did not find published. In practice the operative documents are the DNFM's form, checklist and DAIM procedure. Does an Indian manufacturer need WHO prequalification to supply Timor-Leste? No, but it changes the route. WHO prequalification is named on the form as a Route A qualifier, so a WHO-prequalified product takes the abridged route. Without it an Indian product goes to Route B. WHO prequalification is product- and site-specific; WHO-GMP certification by an Indian state licensing authority is a different thing, is not named on the form, and we found no instrument treating the two as equivalent. Who buys injectables in Timor-Leste? Mainly the state. SAMES was succeeded by the Instituto Nacional de Farmácia e Produtos Médicos under Decree-Law 57/2023, which procures, stores and distributes from a central warehouse in Dili and regional units at Ainaro, Baucau and Maliana. It publishes tenders and results with budgets, winning bidders and amounts; our own approximate count of its published medicine awards is twelve lines worth about USD 2.01 million. Suppliers must hold a valid import or wholesale licence to bid. Does Farbe Firma have experience with ASEAN and Asia-Pacific markets? Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, including Asia-Pacific markets where the ASEAN Common Technical Dossier is the working format. We prepare dossiers in CTD and ACTD structure, generate Zone IV stability data, supply the WHO-format CPP and GMP certificate, and work through licensed local importers. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 5, 2026 TL;DR: Bahrain answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with a clear yes and a clear no. The National Health Regulatory Authority's Medicine Licensing Guideline of 20 October 2025 names six fast-track reference authorities (the Gulf Health Council's central registration, SFDA, US FDA, EMA, Swissmedic and MHRA), a second list on its application form, a third list of GMP 'competent authorities' for licensing foreign sites and a nineteen-country pricing basket, and India's CDSCO is on none of them. Absence is not exclusion: the normal 45-working-day pathway is open to any origin that can furnish a legalised WHO-format CPP, a home-regulator GMP certificate, one year of home-market sales, an eCTD dossier and samples for NHRA laboratory testing. The hard knot is site licensing, which as written wants GHC site registration or a Western or Japanese GMP certificate — for a sterile product, for both bulk manufacturer and batch releaser. The commercial gate is consolidating under the Supreme Council of Health's unified-procurement committee, with the Health Insurance Fund as the government's importer. Key Takeaways A named list, and India is not on it. Fast-track registration in ten working days requires prior approval by the GHC central committee, SFDA, US FDA, EMA, Swissmedic or MHRA; the application form separately asks whether the product is licensed by the GHC, US FDA, Health Canada, TGA, EMA or nine European agencies. There is no WHO-prequalification or generic stringent-authority clause to argue under, and the WHO's August 2026 maturity list places CDSCO at level 3 for vaccines only. The normal pathway is a certificate test. Forty-five working days; a legalised WHO-format CPP from the batch-releaser's country; a country-of-origin GMP certificate; at least one year on the home market; an eCTD dossier to GHC and ICH structure; NHRA laboratory analysis before first import — 50 ampoules, 25 vials or 20 prefilled syringes; a five-year licence cancelled if the product is not marketed within two. A licensed Bahraini pharmacy acts as local agent; the distributor cannot be the marketing-authorisation holder. Site licensing is the knot. Before any product application the foreign site needs an NHRA licence, and checklist item 12 asks for a GHC site-registration certificate or, failing that, a GMP certificate from one of eleven authorities — EudraGMP, Ireland, Germany, France, MHRA, US FDA, Health Canada, TGA, Medsafe, Swissmedic or Japan — beside the home-country GMP certificate; sterile products need licences for both bulk manufacturer and batch releaser. Whether NHRA accepts alternatives in practice we could not verify, so the practical Indian route begins with GHC site registration. Price is set by a basket India is not in. The generic CIF price is the lowest of origin ex-factory plus freight, the lowest CIF in Kuwait, Oman, Qatar, Saudi Arabia, the UAE, Egypt, Jordan, Turkey and eleven Western markets, the price of similar registered drugs, or a ladder that cuts each successive generic; CIF is fixed in US dollars at 0.377 dinars. Buyers are consolidating under the Supreme Council of Health's unified-procurement committee, and adult diabetes prevalence was 22.1% in 2024. Introduction: Why Bahrain Demands a Premium Injectable Manufacturer in Bahrain Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Bahrain, the first Gulf market in the series, answers with unusual precision, because the National Health Regulatory Authority writes its lists down. The operative text is the NHRA Medicine Licensing Guideline, version 4.1 of 20 October 2025, which we read in full. Its fast-track pathway — ten working days against forty-five for the normal route — is open only to products already approved by the Gulf Health Council's central registration, Saudi Arabia's SFDA, the US FDA, the EMA, Swissmedic or the UK's MHRA, with the batch-release site registered with one of them. The application form asks separately whether the product is licensed by the GHC, the US FDA, Health Canada, the TGA, the EMA or the agencies of nine European countries, and the bioequivalence-centre rule accepts GHC-approved sites or those approved by the WHO, US FDA, Health Canada, TGA, MHRA or EMA. India appears in none of these lists, and there is no WHO-prequalification clause, no maturity-level clause and no generic stringent-authority clause anywhere in the guideline under which an Indian approval might be argued in. So the answer to the standing question is a plain no, and the more useful question is what the no costs. It does not cost market access. The normal pathway does not discriminate by country of origin; what it demands is paper and product: a WHO-format certificate of a pharmaceutical product, legalised and issued in the batch-releaser's country, a GMP certificate from that country's health authority, proof that the medicine has been marketed at home for at least one year, an eCTD dossier to the GHC and ICH common technical document, and samples for mandatory laboratory analysis before the first importation — 50 ampoules, 25 vials, 20 prefilled syringes or 5 units of a small-volume solution, with reference standards and full methods — quantities the guideline itself calls approximate and subject to change. A licence runs five years and is cancelled if the product is not marketed within two. The fee schedule sits in a 2016 resolution we could not fetch, so the only figure we print is the 50-dinar hospital-pack fee. A premium injectable manufacturer in Bahrain, then, treats the certificate test as a discipline rather than a formality — and solves the site-licensing problem before filing a single product. What Sets a World-Class Injectable Manufacturer in Bahrain Apart The site-licensing problem is the real gate. NHRA's International Manufacturing Site Licensing Procedure, version 1.6 of the same October 2025 date, makes licensing of the foreign manufacturing site mandatory before any product application. Item 12 of its checklist asks for a valid Gulf Health Council site-registration certificate or, if the applicant cannot supply one, a GMP certificate from a named competent authority — EudraGMP, Ireland's HPRA, Germany, France's ANSM, the MHRA, the US FDA, Health Canada, the TGA, New Zealand's Medsafe, Swissmedic or Japan's health ministry — and item 13 separately requires the GMP certificate of the country of origin. For sterile formulations both the bulk manufacturer and the batch releaser must hold NHRA site licences. The licence is assessed in thirty working days, runs five years and lapses if no product is registered within three. As written, an Indian site with only Indian GMP certification cannot satisfy item 12; whether NHRA exercises discretion in practice we could not verify and do not assert. The honest consequence is that the Indian route to Bahrain begins in Riyadh rather than Manama: with the GHC's central registration committee, created by the Gulf health ministers in 1998, which inspects factories and registers companies under unified regulations, and whose registration Bahrain accepts as a fast-track reference, as a substitute for the CPP and as a substitute for the competent-authority GMP certificate. Two further layers deserve care. First, the GHC's own reference-authority text was not obtained; the only description we found is a 2022 academic evaluation, based on GHC data, reporting that a product approved by two Gulf states or by the US FDA, the EMA or WHO prequalification receives an abridged review, that reliance began at the end of 2019, and that generics are within scope. We report that as the literature's account, not the GHC's rule. Second, the pricing regime. Annex IV of the licensing guideline and the Medicine Pricing Guideline of January 2022 require prices in Kuwait, Oman, Qatar, Saudi Arabia and the UAE and in Australia, Belgium, Canada, Denmark, Egypt, France, Germany, Ireland, Jordan, Spain, Sweden, Switzerland, Turkey and the UK, plus the country-of-origin prices. A generic's CIF price is the lowest of four figures: origin ex-factory plus freight, the lowest CIF anywhere in the basket, the price of similar registered products, or a ladder under which the innovator drops 20% on first generic entry and each successive generic is priced 15%, then 10%, below the one before. CIF is fixed in US dollars at 0.377 dinars, retail is 1.35 times CIF up to 20 dinars and 1.25 above, and prices are revisited at renewal and whenever the home-market price falls. An Indian ex-factory price therefore sets a ceiling, never a floor. Quality Systems Behind Every Injectable Supplied to Bahrain For a sterile injectable the evidence an assessor or inspector expects is the same in Manama as anywhere: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A and Q1B stability data for a hot, humid Gulf climate under the GCC stability guideline NHRA cites. Because analysis by an NHRA-authorised laboratory is mandatory before the first import and a second failure means rejection, the certificate of analysis, reference standards and methods that accompany the samples must be written to be reproduced by a laboratory that has never seen the product. The international layers are quickly stated. Bahrain's NHRA does not appear on the WHO's August 2026 list of authorities at maturity level 3 or 4; the only Gulf authority on it is Saudi Arabia's SFDA, at level 4. India's CDSCO appears on that list for vaccines only, so even a generic maturity-level clause would not carry a small-molecule injectable from India, and Bahrain has no such clause in any case. Neither Bahrain nor India is a PIC/S participating authority. The Indian Pharmacopoeia Commission's recognition list of 10 July 2026 names twenty-four countries and no Gulf state, and the NHRA form asks for the pharmacopoeial standard of each ingredient, so the file should cite the USP, BP or Ph. Eur. monograph where one exists. The founding law, No. 38 of 2009, has not been superseded; Decree-Law 12 of 2023 amended it to move narcotic and psychotropic licensing to NHRA. The leaflet must be supplied in Arabic and English and the SmPC in English. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Bahrain for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries, among them Gulf and Middle Eastern markets where the GHC eCTD structure and GCC stability conditions are the working standard. We build dossiers in CTD and ACTD format, which is the structure NHRA requires in eCTD, and we supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course. Because the guideline requires import and distribution through a licensed Bahraini pharmacy acting as local agent under a legalised contract, our route is a named pharmacy-agent in Bahrain, GHC site registration for the sterile line as the first regulatory act, and a price file built from the basket rather than from our list price. The bilateral relationship is large and the pharmaceutical line in it is new. The Ministry of External Affairs brief of June 2024 records bilateral trade of USD 1,738.86 million in 2023–24, with Indian exports of USD 909.42 million, and names 'medicaments' among India's exports as a recent addition, beside rice, meat, sugar, machinery, jewellery and polymers. There is a health instrument: a memorandum on cooperation in healthcare signed in July 2018, under which an India–Bahrain Joint Working Group on Healthcare first met on 22 February 2022; NHRA's chief executive attended Pharmexcil's iPHEX and regulators' conclave in New Delhi in September 2022. We found no agreement between NHRA and CDSCO. Reports of the fifth High Joint Commission in New Delhi on 3 November 2025 say the two sides agreed to begin negotiating a comprehensive economic partnership agreement; no such agreement exists yet. UN Comtrade's public preview returns Indian pharmaceutical exports to Bahrain of about USD 8.7 million in 2024 and USD 9.4 million in 2025, but flags every record as an estimate, so we quote the order of magnitude and nothing finer. The Indian community, which the two MEA briefs put at 340,000 and 350,000, is roughly a quarter of the population. Where the money is: Bahrain has 1.60 million people, gross national income per capita of USD 28,790 in 2025, current health expenditure of about USD 1,176 per person and 4.0% of GDP in 2023, and life expectancy of 81.4 years. Out-of-pocket payments were 28.7% of health expenditure in 2023 and rising, and diabetes prevalence among adults was 22.1% in 2024, up from 19.5% in 2011; the UNDP investment case for Bahrain is reported to attribute three quarters of deaths to the four main non-communicable diseases. Public purchasing is being consolidated under the Supreme Council of Health, whose National Committee for Unified Procurement of Medicines and Medical Supplies approves purchase contracts, holds the strategic national stock and prepares the essential-medicines list, and whose membership names the buyers: the Health Insurance Fund as vice-chair and, per the health minister's 2024 statement, the government's importer of record; King Hamad University Hospital; the Bahrain Defence Force Hospital; the Bahrain Oncology Center; the specialist cardiac centre; the government hospitals; and primary care. Ministry of Health tenders are advertised through the Tender Board portal, and the committee's brief includes increasing Bahrain's share of the GCC Joint Procurement Programme, whose 2026 tender schedule is published and whose supplier prerequisites we could not obtain. Hospital pack sizes supplied to tenders must be registered with NHRA, and injectable hospital packs of one to ten units are not accepted unless they are at least five times the largest registered pack. The national health insurance law of 2018 is the frame for all of it; the pace of its rollout in 2026 we report only as claimed. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Bahrain's list of recognised regulatory authorities? No. NHRA's Medicine Licensing Guideline of 20 October 2025 names the GHC central registration, SFDA, US FDA, EMA, Swissmedic and MHRA as fast-track reference authorities, lists the GHC, US FDA, Health Canada, TGA, EMA and nine European agencies on its application form, and lists eleven Western and Japanese authorities as GMP 'competent authorities' for site licensing; CDSCO is on none, and there is no WHO-prequalification or maturity-level clause. Absence is not exclusion: the normal 45-working-day pathway accepts a legalised WHO-format CPP and GMP certificate from India once the site is licensed by NHRA. What law governs medicine registration in Bahrain? Decree-Law 18 of 1997 on the practice of pharmacy, amended by Decree-Law 20 of 2015, with Resolution 63 of 2019 and the Supreme Council of Health's registration and pricing regulation, Resolution 32 of 2020 as amended by Resolution 46 of 2023; NHRA itself was created by Law 38 of 2009, amended by Decree-Law 12 of 2023. The operative rules are NHRA's Medicine Licensing Guideline version 4.1 and Site Licensing Procedure version 1.6, both of 20 October 2025, and the Pricing Guideline of January 2022. Dossiers are eCTD; licences run five years; fees follow Decree 17 of 2016, whose schedule we could not fetch. Can an Indian manufacturer get its site licensed by NHRA? As written, only with a Gulf Health Council site-registration certificate or a GMP certificate from one of eleven listed authorities — EudraGMP, Ireland, Germany, France, the MHRA, US FDA, Health Canada, TGA, Medsafe, Swissmedic or Japan — in addition to the Indian GMP certificate. Whether NHRA accepts alternatives in practice we could not verify. For a sterile product both the bulk manufacturer and the batch releaser need licences. The practical sequence is GHC site registration first, then the NHRA site licence, then the product. Who buys injectables in Bahrain? Government purchasing is consolidating under the Supreme Council of Health's National Committee for Unified Procurement, with the Health Insurance Fund as the government's importer and King Hamad University Hospital, the Bahrain Defence Force Hospital, the Bahrain Oncology Center, the cardiac centre, the government hospitals and primary care at the table; Ministry of Health tenders are advertised through the Tender Board portal, and Bahrain takes part in the GCC Joint Procurement Programme. Every product reaches the market through a licensed Bahraini pharmacy as local agent, and hospital pack sizes must be registered with NHRA before they can be tendered. Does Farbe Firma have experience with GCC markets? Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, including Gulf and Middle Eastern markets. We prepare dossiers in CTD and ACTD format to the GHC and ICH eCTD structure, generate stability data under GCC conditions, supply the WHO-format CPP, manufacturing licence and GMP certificate, and work through licensed local agents with Arabic and English leaflets. Write to director@farbefirma.org with the product list and we will map it to the NHRA pathway and the pricing basket. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 5, 2026 TL;DR: Trinidad and Tobago answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with three layered lists, India on none of them, and Indian factories nonetheless the largest source of the medicines it registers and buys. The Food and Drugs Regulations of 1964 name Canada, the United States, the United Kingdom and Australia plus a ministerial-discretion clause; the Chemistry, Food and Drugs Division's notice of 4 November 2022 names the WHO's stringent authorities for biologics and, for small molecules and generics, six PAHO level-4 authorities, the EU-27 and the UK, as the sources of the CPP it relies on 'to expedite'; the Caribbean Regulatory System in Port of Spain relies on PAHO reference authorities, ICH and WHO level-3 agencies, or WHO prequalification. CDSCO's own level-3 listing is for vaccines only. The gate is a certificate-origin test — an apostilled CPP from a listed authority, an Indian GMP certificate, Zone IVb stability, three samples, TT$750 and a 120-day clock — and India tops the register every year from 2022 to 2025 and supplies about three fifths of NIPDEC's 2025–26 injectable award lines. Since 4 July 2025 the country also recognises the Indian Pharmacopoeia: a standards opening, not regulatory reliance. Key Takeaways Three lists, kept apart, and India on none. The Regulations: a certificate from Canada, the US FDA, the UK or Australia, or from a body the Minister considers adequate. The CFDD notice of November 2022: EMA, US FDA, Health Canada, Swissmedic, Medsafe, TGA and MHRA for biologics; ANMAT, ANVISA, CECMED, INVIMA, COFEPRIS and ISP, the EU-27 and the UK for small molecules and generics. The CRS guidance of November 2020: PAHO reference authorities plus ICH and WHO level-3 agencies, or WHO prequalification. What happens to a CPP from an unlisted authority is stated nowhere. The mechanics are old and cheap. The Food and Drugs Act, Chapter 30:01 of 1960, last amended in 2005 and not superseded, requires a Form C submission in four sections rather than CTD, electronic since November 2022, with an apostilled CPP, a GMP certificate from the manufacturing country's regulator — for an Indian site, the Indian one — Zone IVb stability on three lots, three finished samples, TT$750 and a statutory decision within 120 days. No validity period or renewal was found. Injectable antibiotics fall under a separate Antibiotics Act we did not read. India is already the largest supplier. On the CFDD register India is the leading country of origin in every year from 2022 to 2025; on the CRS registry Indian marketing-authorisation holders account for the largest share of roughly 337 recommendations; and in NIPDEC's 2025–26 award list of 1,458 lines about 48% of all lines and about 59% of the 409 injectable lines are Indian-made, by our approximate count. Which certificate each product used is not visible, so we do not say Trinidad and Tobago relies on CDSCO — only that the certificate-origin gate has not kept Indian injectables out. The buyer is NIPDEC, and it is under pressure. A National Insurance Board subsidiary contracted since 1993 to run the health supply chain for the Ministry of Health and five regional health authorities, and since 2003 the Chronic Disease Assistance Programme — fifty-one items through 275 private pharmacies on one NIPDEC page, fifty-three through about 257 on another — buying under the Public Procurement and Disposal of Public Property Act 2015. Out-of-pocket payments were 45.3% of health spending in 2023, adult diabetes prevalence 12.4% in 2024, and press reports of programme shortages in May 2026 cite supplier-payment delays — reported, not verified. Introduction: Why Trinidad and Tobago Demands a Premium Injectable Manufacturer in Trinidad and Tobago Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Trinidad and Tobago is the first market in the series to answer with three lists at once, and the discipline is to keep them apart. The oldest is statutory: Division 3 of the Second Schedule to the Food and Drugs Regulations, made under the Food and Drugs Act, Chapter 30:01, requires a new-drug submission for an imported medicine to include a Canadian notice of compliance, a US FDA certificate, a certificate from the UK or Australian health authorities, or a certificate in English from an official body 'considered by the Minister as adequate', with a further paragraph allowing the Minister to accept detailed safety reports instead. The second is administrative: the Chemistry, Food and Drugs Division's notice to importers of 4 November 2022 tells applicants where to obtain the certificate of pharmaceutical product — for biologics, from the WHO's stringent regulatory authorities; for small molecules and generics, from the six PAHO level-4 authorities of Argentina, Brazil, Cuba, Colombia, Mexico and Chile, the twenty-seven EU member states and the UK — and adds in a footnote that the Division relies on previous approval by those authorities 'to expedite the approval process'. The third is regional: the Caribbean Regulatory System, run by CARPHA from Port of Spain, whose guidance of November 2020 lists PAHO reference authorities and ICH or WHO level-3 agencies, and admits WHO-prequalified products by a second pathway. India's CDSCO is on none of the three, and its own place on the WHO's August 2026 maturity list is at level 3 for vaccines only, so the CRS's level-3 clause does not reach an Indian small-molecule injectable. What the lists do not say matters as much. The 2022 notice defines a reference authority as the country from which the CPP was issued, so the gate is a certificate-origin test layered on an agency list; it does not state what happens to a CPP from an unlisted authority, and we found no text that refuses one, nor any that accepts one. Beside the CPP, the Division's detailed requirements ask for a GMP certificate 'issued by the drug regulatory authority of the manufacturing country' — for an Indian site, the Indian certificate — and the Act's own border rule requires every imported drug to conform to the law of the country where it was made and to carry that country's official certificate. A premium injectable manufacturer in Trinidad and Tobago is therefore one that holds a listed-authority CPP or WHO prequalification for the product, an Indian GMP certificate for the site, and a dossier written for a 120-day statutory clock. What Sets a World-Class Injectable Manufacturer in Trinidad and Tobago Apart The paradox that sets this market apart is that the lists have not kept India out. The Division's own register of drugs approved from 1999 to 2025, published in December 2025, shows India as the leading country of origin in every year from 2022 to 2025 — by our approximate count of entry lines, 157 of 476 in 2025 — and the entries made after the November 2022 notice include sterile injectables from Aspiro, Venus Remedies, Troikaa, Zydus Hospira, Caplin Point, Gland Pharma, Divine Laboratories, TherDose and Emcure. The CRS registry, queried in September 2026, returned roughly 337 recommendations, roughly 214 of them active, and Indian marketing-authorisation holders dominate it — Hetero, Intas, Macleods, Venus, Troikaa and Aculife among them — with active injectables including midazolam, bupivacaine, propofol, dopamine, irinotecan and piperacillin-tazobactam. By the CRS's rules each of those rested on a listed reference-authority registration or on WHO prequalification, and neither register shows which; we therefore do not say that Trinidad and Tobago relies on CDSCO, only that Indian sites holding EU, UK, US, Australian or PAHO level-4 registrations, or WHO-prequalified products, pass the gate routinely. The mechanics are worth stating exactly, because they are unlike the CTD-driven regimes elsewhere in this series. Submission is on Form C in four dossiers — administrative, chemical, clinical including bioequivalence, and manufacturing and packaging — in duplicate, electronic since 4 November 2022 with a hard-copy administrative folder of original or apostilled certificates presented by appointment. The fee is TT$750 per drug and TT$100 per variation. The Regulations require the Minister, on the Drug Advisory Committee's recommendation, to notify within 120 days of filing. Stability must cover at least three lots, accelerated and long-term, for climatic Zone IVb; three finished samples are required, and the two Division documents disagree on whether samples of the active ingredient are needed, so we report both. Labels and inserts are in English and parenterals must carry the lot number. No validity period or renewal was found: a notice of approval stands until withdrawn by Gazette. Antibiotics are carved out to the Antibiotics Act, Chapter 30:02, which we did not read, so injectable antibiotics may follow a different route. Whether a local agent is legally mandatory we could not establish; the Regulations allow the manufacturer or the importer to file, the practice is importer-led, and the CRS notes that the national stage requires an importer or distributor to be identified. Quality Systems Behind Every Injectable Supplied to Trinidad and Tobago For a sterile injectable the evidence an assessor expects is the same: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity — the Division specifically asks for the sterility of container surfaces — sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, a process description down to lyophilisation where applicable, and ICH Q1A and Q1B stability generated for Zone IVb rather than extrapolated from a temperate zone. Because the Act lets customs inspectors sample and hold a consignment pending an analyst's report, the certificate of analysis and methods for each batch should be written to be reproduced by an outside laboratory. The international layers are quickly stated. Trinidad and Tobago does not appear on the WHO's August 2026 list of authorities at maturity level 3 or 4, and no published benchmarking result for it was found; India's CDSCO appears on that list for vaccines only. Neither country is a PIC/S participating authority. The founding Act of 1960 has not been superseded, and we found no bill to create a standalone drug regulatory authority, so we do not report one. The one India-specific gate that has opened is on the standards side: during the Prime Minister of India's state visit on 3 and 4 July 2025 the two governments signed a memorandum on pharmacopoeial cooperation under which Trinidad and Tobago recognises the Indian Pharmacopoeia for the quality standards of medicines, and the country appears on the Indian Pharmacopoeia Commission's recognition list of 10 July 2026. That is compendial recognition, not regulatory reliance; we found no amendment to the Regulations giving the IP legal standing, and it does not change the CPP requirement. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Trinidad and Tobago for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries, including English-speaking markets in the Caribbean and Latin America. We build dossiers in CTD and ACTD format and remap them without loss to the Division's four-section Form C structure, and we supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course. Because the certificate-origin test is the gate, we tell buyers plainly which of our products carry a listed-authority CPP or WHO prequalification and which do not, and we work through a registered importer in Port of Spain who files, identifies the distributor, and registers with NIPDEC as a supplier. The bilateral relationship is deep and, since July 2025, unusually specific about medicines. The Ministry of External Affairs brief of June 2025 records bilateral trade of USD 341.61 million in 2024–25, with Indian exports of USD 120.65 million and imports of USD 220.96 million, after a record USD 368.96 million the year before, and names pharmaceutical products among India's principal exports beside vehicles, iron and steel and plastics; the brief adds that much trade moves indirectly through North America and Europe. UN Comtrade's public preview puts Indian pharmaceutical exports to Trinidad and Tobago at about USD 23.3 million in 2024 and USD 18.9 million in 2025. The health instruments are a memorandum on traditional medicine of 2012, an Ayurveda chair and a medicinal-plants memorandum with the University of the West Indies, and, from the July 2025 state visit, the Indian Pharmacopoeia memorandum, a gift of twenty haemodialysis units and two sea ambulances, 'Heal in India' treatment, and overseas-citizen eligibility extended to the sixth generation of a diaspora the two MEA briefs put at 42% and 40–45% of the population. The joint statement records the Indian Prime Minister commending the recognition of the Indian Pharmacopoeia as a step to 'quality and affordable generic medicines from India'. We found no line of credit. Where the money is: Trinidad and Tobago has 1.37 million people, gross national income per capita of USD 18,550 in 2025, down for three consecutive years, current health expenditure of about USD 1,276 per person and 7.5% of GDP in 2023, and life expectancy of 73.6 years. Out-of-pocket payments were 45.3% of health expenditure in 2023, diabetes prevalence among adults was 12.4% in 2024, tuberculosis incidence has risen to 27 per 100,000, and the last official renal figure we found put 1,187 patients on renal replacement therapy in May 2018, about 875 per million, with no national registry since. The public buyer is NIPDEC, a subsidiary of the National Insurance Board contracted since October 1993 to run the health supply chain from its central stores at Chaguaramas for the Ministry of Health and the North West, North Central, Eastern, South West and Tobago regional health authorities, and since February 2003 the Chronic Disease Assistance Programme, whose basket of fifty-one items for eleven non-communicable diseases is dispensed free through 275 private pharmacies, figures NIPDEC's own pages give inconsistently, another stating fifty-three items and about 257 dispensing points. NIPDEC registers suppliers on a procurement form, tenders through an electronic portal and, unusually, publishes its award list: the 2025–26 pharmaceutical awards run to 1,458 lines, of which by our approximate count about 48% are Indian-made, rising to about 59% of the 409 injectable lines — dialysis solutions, oncology, insulins and biosimilars, anaesthesia and intensive-care injectables — from Neon, SG Pharma, Getwell, Gland, Dr Reddy's, Venus, Troikaa, Sun, Intas and Biocon among others. Private distribution is concentrated in Agostini's, which owns Smith Robertson and the SuperPharm chain and bought the Aventa group in June 2024, and in Bryden pi. Press reports in May 2026 described programme shortages that the Ministry denied and the pharmacists' society attributed in part to supplier-payment delays; we report both. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Trinidad and Tobago's list of recognised regulatory authorities? No, on any of the three layers. The Regulations name Canada, the US FDA, the UK and Australia plus a ministerial-discretion clause; the CFDD notice of November 2022 names the WHO stringent authorities for biologics and six PAHO level-4 authorities, the EU-27 and the UK for small molecules and generics; the CRS lists PAHO reference authorities and ICH or WHO level-3 agencies, and CDSCO's level-3 status covers vaccines only. The gate is the origin of the CPP, not the location of the factory: India tops the register every year from 2022 to 2025. We neither claim nor deny that a CDSCO-only CPP would be accepted; no text answers that. What law governs medicine registration in Trinidad and Tobago? The Food and Drugs Act, Chapter 30:01 of 1960, last amended by Act 6 of 2005 and not superseded, with the Food and Drugs Regulations of 1964, administered by the Chemistry, Food and Drugs Division of the Ministry of Health with a Drug Advisory Committee. A new drug needs a Form C submission in four sections, an apostilled CPP or free-sale certificate, a GMP certificate from the manufacturing country's regulator, Zone IVb stability on three lots, three samples and TT$750; the Minister must notify within 120 days. No validity period was found; antibiotics fall under the separate Antibiotics Act, Chapter 30:02. Does the Indian Pharmacopoeia memorandum of July 2025 change the registration route? Not as far as we can verify. The memorandum, signed during the Indian Prime Minister's state visit on 3 and 4 July 2025, commits Trinidad and Tobago to recognise the Indian Pharmacopoeia for the quality standards of medicines, and the country is on the Indian Pharmacopoeia Commission's July 2026 recognition list. That is recognition of a compendium, not reliance on a regulator: we found no amendment to the Regulations giving the IP legal standing and nothing that alters the reference-authority CPP requirement. It is nonetheless the only India-specific opening in this market, and it is real. Who buys injectables in Trinidad and Tobago? NIPDEC, the National Insurance Board subsidiary contracted since 1993 to supply the Ministry of Health and the five regional health authorities and to run the Chronic Disease Assistance Programme, buying under the Public Procurement and Disposal of Public Property Act 2015 through registered suppliers and an electronic tender portal; its 2025–26 award list sources about three fifths of its injectable lines from India. Private demand, where out-of-pocket payments are 45.3% of health spending, runs mainly through Agostini's Smith Robertson and SuperPharm businesses and through Bryden pi, and through private hospitals such as St Clair, Westshore and Medical Associates. Does Farbe Firma have experience with Caribbean and CARICOM markets? Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, including English-speaking Caribbean and Latin American markets. We prepare dossiers in CTD and ACTD format and remap them to the Division's Form C structure, generate Zone IVb stability, supply the WHO-format CPP, manufacturing licence and GMP certificate, and work through registered local importers. Write to director@farbefirma.org with the product list and we will tell you, product by product, which certificate route applies. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 4, 2026 TL;DR: Equatorial Guinea answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with no list at all, because its gate is a certificate test rather than an agency test. Ley del Medicamento 3/2003 requires every imported lot to be lodged with the Ministry of Health and Social Welfare with its invoices and a quality certificate under the WHO certification scheme, or failing that the supplying laboratory's own, and forbids import or customs release without the Ministry's prior authorisation. The registry, quality-control laboratory and essential-medicines list the same law promised are written in the future tense, and we found none operating, nor any published guideline, fee, timeline or dossier format; the regulator is a directorate general inside the Ministry, not a standalone agency. India appears twice: in a Ministry resolution concerning the Indian firm named in the WHO alert of October 2022, which we could not read, and by absence from the Indian Pharmacopoeia Commission's July 2026 list of recognising countries. Equatorial Guinea has signed but not ratified the African Medicines Agency treaty and is absent from the WHO maturity list. The commercial gate is a licensed local distribution warehouse: the State buys through CENTRAMED, named private distributors source largely through Spain, and the Prime Minister reported in December 2024 that more than 1,500 million CFA francs of government medicines were expiring in the central warehouses. Key Takeaways A certificate test, not an agency test. Article 18 of Ley 3/2003 requires distribution warehouses to lodge, for each imported lot, the invoices and a quality certificate according to the scheme established by the WHO, or failing that the supplying laboratory's own certificate; Article 19 bars import or customs release without prior Ministry authorisation; Article 3 allows only Ministry-authorised products on the market. No reference-authority list exists to be on or off, and no country-of-origin rule was found. A law but not yet a visible regulator. The regulator is the Directorate General for Supply, Pharmacy, Biomedical Laboratories and Blood Bank within the Ministry; no standalone agency exists. The registry, quality-control laboratory and essential-medicines list that Article 6 says will be created could not be found in operation; dossier format, fees, timelines, validity and sample rules are all unpublished. Article 5 admits a new medicine only if it offers an advantage over a similar product already authorised, and Article 61 sends suspect lots to a reference laboratory of the subregion. India is mentioned, but not in a way we can read. The Ministry's legal-documents page lists a ministerial resolution concerning Maiden Pharmaceuticals, the Indian company named in the WHO alert of October 2022; the file is a scanned image without readable text, so we do not characterise its scope or whether it remains in force. The Indian Pharmacopoeia Commission's recognition list of 10 July 2026 does not include Equatorial Guinea, although two Ministry officers attended the commission's policymakers' forum in August 2024. Equatorial Guinea is absent from the WHO's maturity list, on which India's CDSCO is level 3 for vaccines only. The buyer is a licensed warehouse, and the State's own is under scrutiny. Articles 15 to 17 reserve import, distribution and sale to Ministry-authorised distribution warehouses with a pharmacist as technical director and, under Article 22, minimum capital of 50 million CFA francs. CENTRAMED is the state purchasing centre, and the Ministry names COFARMA, SANTIFARMA, GEFARMA, GLOBALFARMA and MUNDOFARMA as the private distributors it relies on. In December 2024 the Prime Minister inspected CENTRAMED, found expired stock and inadequate cold rooms, and put the value of expiring government medicines above 1,500 million CFA francs. Out-of-pocket payments were 66% of health spending in 2023. Introduction: Why Equatorial Guinea Demands a Premium Injectable Manufacturer in Equatorial Guinea Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Equatorial Guinea is the clearest case yet of a market where the question has no object, because the law does not gate on who approved a medicine but on what paper travels with each consignment. The statute is Ley del Medicamento 3/2003 of 18 November 2003, published in the official gazette, which repealed a decree of 1991 and came into force a year after publication; we read it in full and found no reference to reference countries, stringent authorities or reliance. Article 18 requires the licensed distribution warehouses to lodge with the Ministry of Health and Social Welfare, for each imported lot, the corresponding invoices and quality certificates according to the scheme established by the WHO — the WHO certification scheme for products moving in international commerce — or, failing that, the supplying laboratory's own, which may be a single certificate per laboratory. Article 19 provides that nothing covered by the law may be imported or released from customs without the prior authorisation of the competent Ministry services, and Article 3 that only products the Ministry has authorised may be sold. So the honest answer is that there is no list, and that a WHO-format certificate of a pharmaceutical product is the document that matters. The harder question is who examines it. The 2023 organisation chart of the Ministry lists seven directorates general, and the one with the mandate is the Directorate General for Supply, Pharmacy, Biomedical Laboratories and Blood Bank; there is no separate regulatory agency, and the widely repeated reference to a Law 1/2000 on pharmaceutical products could not be found in any legal database, so we treat Ley 3/2003 as the law in force. That law establishes marketing authorisation and pharmaceutical registration at the Ministry, but says that a quality-control laboratory and an authorised essential-medicines list will be created, in the future tense, and we found neither a public register of authorised products nor any registration guideline, application form, fee schedule, timeline, validity period, sample rule or prescribed dossier format. A premium injectable manufacturer in Equatorial Guinea is therefore one that can supply, for every lot, the WHO-scheme certificate, the batch documentation and the stability evidence that a small directorate can examine without a laboratory of its own. What Sets a World-Class Injectable Manufacturer in Equatorial Guinea Apart The market structure is written into the statute. Articles 15 to 17 reserve import, distribution and sale of medicines to distribution warehouses authorised by the Ministry, which alone may supply pharmacies and health centres; Article 22 conditions a warehouse licence on, among other things, presidential authorisation for foreign investment, tax and criminal-record certificates, plans of the premises and minimum capital of 50 million CFA francs, and every warehouse must have a pharmacist as technical director. Article 45 allows the Ministry to authorise pharmacy-level import only for specialities not available in the country. Article 5 sets the authorisation criteria, including reasonable cost, and adds that a new medicine may be added only if it represents an advantage over a similar product already authorised — a formal preference for what is already on the market that a new entrant must argue against. Article 8 tiers products by the level of facility, from health post to hospital, and Article 14 requires local manufacturers to follow WHO good manufacturing practice. Every document we read, from the law to the ministerial orders to the organisation chart, is in Spanish. India appears in this record in two places, and both deserve care. The Ministry's page of legal documents lists a ministerial resolution concerning the case of Maiden Pharmaceuticals, the Indian manufacturer named in the WHO product alert of October 2022; the linked file is a scanned image with no machine-readable text, so we could not establish what it orders, whom it covers or whether it remains in force, and we do not describe it as a ban, a restriction or as lifted. Separately, the Indian Pharmacopoeia Commission's list of countries recognising the Indian Pharmacopoeia, updated on 10 July 2026, does not include Equatorial Guinea, although two senior Ministry officers attended the commission's policymakers' forum in August 2024 — attendance, not recognition. Beyond India, the regional layer is CEMAC, the Central African Economic and Monetary Community: its heads of state adopted a common pharmaceutical policy in June 2013 and charged its health agency OCEAC with harmonising national policies, and OCEAC ran a joint marketing-authorisation assessment workshop in Brazzaville from 8 to 12 December 2025 with pharmacy experts from all six member states, at which fewer than fifteen dossiers were assessed. Equatorial Guinea's delegation was not separately named, and in the draft protocol for a CEMAC pooled-purchasing mechanism the cell naming each state's central purchasing agency is filled for five states and blank for Equatorial Guinea. Quality Systems Behind Every Injectable Supplied to Equatorial Guinea For a sterile injectable the evidence any assessor or inspector expects is the same: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A and Q1B stability data for a hot, humid equatorial climate rather than data extrapolated from elsewhere. Because Article 61 of the law directs suspect lots to a reference laboratory of the subregion and no national quality-control laboratory is identified as operational, the certificate of analysis for each batch should be written to be reproduced by an outside laboratory, with methods that a modest facility can run, and the WHO-scheme certificate should travel with every lot, not just the first. The international layers are quickly stated. Equatorial Guinea does not appear on the WHO's August 2026 list of authorities at maturity level 3 or 4, and no published benchmarking result for it was found; India's CDSCO appears on that list for vaccines only, so a generic clause admitting products approved by a level-3 authority would not carry a small-molecule injectable from India — we found no such clause here, and note it only so that a buyer reads any future CEMAC or national reliance provision with the scope column of the WHO list in hand. No PIC/S membership or applicant status was found for Equatorial Guinea. On the African Union's treaty status list of 22 May 2026, Equatorial Guinea signed the treaty establishing the African Medicines Agency on 2 February 2022 and has not ratified or deposited it. The harmonisation programme's country page for Equatorial Guinea exists but is empty. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Equatorial Guinea for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries, including Spanish- and French-speaking markets in Africa. We build dossiers in CTD and ACTD format, which is the structure the CEMAC harmonisation work is reported to adopt and the one any future national guideline is likely to follow, and we supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course — which, under Article 18, is precisely the paper a licensed distribution warehouse must lodge with the Ministry for each lot. Because the law reserves import to authorised warehouses, our route is through a licensed Equatoguinean distributor, with Spanish-language labelling and documentation prepared at source. The bilateral relationship is larger than the market suggests, and it runs on oil. The Ministry of External Affairs brief of February 2026 records bilateral trade of USD 463.32 million in 2024–25, with Indian exports of USD 19.18 million and imports of USD 444.14 million, mainly oil, gas, metal scrap and timber; the total peaked at USD 983.80 million in 2019–20. The brief names pharmaceuticals explicitly among India's exports, alongside food products, cereals, meat, machinery and apparel. The only health-adjacent instrument is a memorandum on cooperation in medicinal plants approved in May 2018; there is no health memorandum, no regulator-to-regulator agreement and no Indian line of credit. What there is instead is a record of medicines as diplomacy: India handed over about 10,000 kilograms of antiretrovirals and HIV diagnostic kits to the Minister of Health on 11 February 2025, anti-tuberculosis medicines in May 2022 and COVID-19 supplies in June 2020, and the first foreign-office consultations were held in Malabo on 10 February 2025, following the state visits of 2018 in both directions. UN Comtrade returned nothing usable for the pharmaceutical trade between the two countries, so no figure is published here. Where the money is: Equatorial Guinea has 1.94 million people, gross national income per capita of USD 5,890 in 2025, down from USD 6,050 the year before, current health expenditure of about USD 234 per person and 3.5% of GDP in 2023, and life expectancy of 63.9 years. Out-of-pocket payments were 66% of health expenditure in 2023, so the private channel is large: the Ministry names COFARMA, SANTIFARMA, GEFARMA, GLOBALFARMA and MUNDOFARMA as the distributors it relies on, and one of them runs a purchasing centre in Valencia, Spain, supplies more than 400 pharmacies and the La Paz hospitals in Malabo and Bata, and describes its products as meeting European legislation — the sourcing default an Indian supplier must displace on documentation and price. The public channel is CENTRAMED, the Central de Compras de Medicamentos, which the Ministry stresses is not the country's only supplier; in December 2024 the Prime Minister inspected its warehouses, found expired stock and inadequate cold rooms, and put the value of expiring government medicines above 1,500 million CFA francs. A programme financed by the Government and the United States Department of Justice procured more than 100 tonnes of essential medicines for all nineteen health districts between 2021 and its scheduled close in 2025, and Equatorial Guinea is on the Global Fund's 2026 eligibility list for HIV, tuberculosis and malaria. Tuberculosis incidence was 199 per 100,000 in 2024 and malaria incidence 228 per 1,000 people at risk; the country is served through Malabo on Bioko island and Bata on the mainland, with Annobón reached by air. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Equatorial Guinea's list of recognised regulatory authorities? There is no list. Ley del Medicamento 3/2003 gates on documents, not on the approving agency: each imported lot must be lodged with the Ministry with its invoices and a quality certificate under the WHO certification scheme, or failing that the laboratory's own, and nothing may be imported or cleared through customs without prior Ministry authorisation. No country-of-origin rule was found. The Ministry does publish a resolution concerning the Indian firm Maiden Pharmaceuticals, which we could not read, and the Indian Pharmacopoeia is not on the commission's July 2026 recognition list. We neither claim nor deny that CDSCO approval carries weight. What law governs medicine registration in Equatorial Guinea? Ley del Medicamento 3/2003 of 18 November 2003, in Spanish, which repealed the 1991 decree. It places marketing authorisation and pharmaceutical registration at the Ministry of Health and Social Welfare, admits a new medicine only if it offers an advantage over a similar one already authorised, requires local manufacturers to follow WHO GMP, and reserves import and distribution to licensed warehouses. The registry, quality-control laboratory and essential-medicines list it announces are written in the future tense, and no dossier format, fee, timeline or validity period is published. Who is the regulator? The Directorate General for Supply, Pharmacy, Biomedical Laboratories and Blood Bank within the Ministry of Health and Social Welfare; there is no standalone medicines agency. Equatorial Guinea is absent from the WHO maturity-level list, has signed but not ratified the African Medicines Agency treaty, and belongs to CEMAC, whose health agency ran joint marketing-authorisation assessments in Brazzaville in December 2025 with experts from all six member states; whether Equatorial Guinea's own products or agencies take part in the CEMAC joint procedures was not confirmed. Who buys injectables in Equatorial Guinea? Licensed distribution warehouses, which the law makes the only lawful importers. The State buys through CENTRAMED, the Central de Compras de Medicamentos, and the Ministry names COFARMA, SANTIFARMA, GEFARMA, GLOBALFARMA and MUNDOFARMA as the private distributors it relies on, several sourcing through Spain. Out-of-pocket payments are 66% of health spending. In December 2024 the Prime Minister reported more than 1,500 million CFA francs of government medicines expiring in CENTRAMED warehouses, so reliable cold-chain documentation and realistic shelf life are commercial arguments here, not formalities. Does Farbe Firma have experience with CEMAC and Spanish-speaking markets? Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, including Spanish- and French-speaking Africa. We prepare dossiers in CTD and ACTD format, supply the WHO-format CPP, manufacturing licence and GMP certificate for every lot, and work through licensed local distributors with Spanish-language documentation. Write to director@farbefirma.org with the product list and we will prepare the warehouse file. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 4, 2026 TL;DR: Guinea-Bissau answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with no published list and a national procedure we could not read. The law that binds it is not national at all: it is the West African Economic and Monetary Union's Règlement 04/2020/CM/UEMOA, which replaced the 2010 regulation and prescribes a five-module CTD dossier, a five-year marketing authorisation, an expert committee and a national medicines commission, a holder located or represented in the country, and a base fee cut by half for medicines made inside the union. Nothing in that text names India, CDSCO or any reference authority, so there is neither an India-specific barrier nor an India-specific shortcut. The regulator is in transition — the 2011 WHO profile names a directorate with no website, while late-2025 sources name a new authority whose founding instrument we could not locate. Guinea-Bissau endorses the ECOWAS harmonisation initiative but is not one of its seven active assessors, has neither signed nor ratified the African Medicines Agency treaty, and is absent from the WHO maturity list. The commercial gate is donor money — sixty million euros of Global Fund grants for 2024 to 2026 — beside a state purchasing centre that announced in February 2025 it would buy again after a decade as a warehouse, and four licensed private importers. Key Takeaways The law is UEMOA law. Règlement 04/2020/CM/UEMOA of 28 September 2020 abrogated Règlement 06/2010 and governs marketing authorisation in all eight member states, Guinea-Bissau included: a CTD in five modules, a five-year authorisation renewable on application lodged 120 days before expiry, review by an expert committee and a national medicines commission, a holder located or represented in the country, and a base fee halved for medicines manufactured within the union. Its validation criteria include the ex-tax wholesale price and the number of similar multi-source products already on the market; origin is not a criterion. No list, and no readable national procedure. No reference-authority, reliance or stringent-regulator list was found in Portuguese or English, and no national fee schedule, timeline, sample rule or local-agent rule was located. The Ministry's website returned no readable content. We therefore neither claim nor deny that India's CDSCO is recognised; the WHO's August 2026 maturity list places CDSCO at level 3 for vaccines only and does not list Guinea-Bissau at all. The regulator is being renamed under our feet. The AMRH country page, built on the WHO profile of 2011, names the Directorate of Pharmaceutical, Laboratory and Drug Services; a September 2025 vendor release and an October 2025 consultancy note name a new regulatory authority for pharmacy, laboratories and medicines that manages the National Drug Catalogue and a track-and-trace mandate signed on 19 September 2025, reported to take effect in March 2026. We could not find the instrument that created the new authority and do not assert that the March deadline was met, since a military takeover intervened in November 2025. The buyer is mostly donor-funded, and the State is trying to buy again. UNDP is principal recipient of the Global Fund malaria grant of thirty million euros for 2024 to 2026, the Ministry of Public Health manages a second grant of the same size for HIV and tuberculosis, and UNICEF delivers vaccines and World Bank-financed consignments. CECOME, the state purchasing centre, announced in February 2025 that it would resume buying essential generics after being unable to since about 2014. Four licensed private wholesale importers were named in 2023, and out-of-pocket payments were 61.6% of health spending, so the retail channel is real but small. Introduction: Why Guinea-Bissau Demands a Premium Injectable Manufacturer in Guinea-Bissau Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Guinea-Bissau gives an answer we have met before, with a twist we have not. No such list exists in any readable form, in Portuguese or in English, and no national registration guideline, fee schedule or timeline could be found; the Ministry of Public Health's website served a loading screen and nothing else. The twist is that the registration law that actually binds Guinea-Bissau is not a Bissau-Guinean statute. As a member of the West African Economic and Monetary Union, the country is bound by Règlement 04/2020/CM/UEMOA on the procedures for authorising human medicines, adopted in Lomé on 28 September 2020, which in its final article abrogates the 2010 regulation that many secondary sources still cite. We read that text in full. It contains no list of reference or stringent authorities and no country-of-origin criterion. Its only reliance clause allows one member state to draw on the technical expertise of another member state's authority and to sit in joint evaluation sessions — reliance inside the union, not on Europe, the United States or India. So the honest position on the standing question is that there is no list to be on or off, and no India-specific barrier or shortcut. What the regulation does prescribe is concrete. Dossiers follow the common technical document in five modules. A marketing authorisation runs for five years, and renewal must be lodged 120 days before it expires. Each file is examined by an expert committee and then by a national medicines commission. The authorisation holder must be located or represented in the country. The base fee is reduced by half for medicines manufactured within the union, a deliberate preference for regional producers that an Indian manufacturer pays in full. And the validation criteria in Article 12 include, beside efficacy and safety, the ex-tax wholesale price, the daily and total cost of treatment, and the number of similar multi-source products already on the market. A premium injectable manufacturer in Guinea-Bissau therefore competes on a complete CTD file and a defensible price in a market that is explicitly allowed to say no because enough equivalents are already registered. What Sets a World-Class Injectable Manufacturer in Guinea-Bissau Apart The first thing that sets a serious supplier apart in this market is knowing who the regulator is this year. The AUDA-NEPAD harmonisation programme's country page, which most compilations copy, names the Directorate of Pharmaceutical, Laboratory and Drug Services under the Ministry of Public Health as the authority for marketing authorisation, inspection, licensing, quality control, pharmacovigilance and import control, states that it has no website of its own, and rests on the WHO pharmaceutical country profile of 2011 — fifteen years old. That page also contradicts itself on whether foreign manufacturers must comply with good manufacturing practice, and runs on into a block of text about Kenya, so we treat it as an unreliable secondary compilation rather than as law. More recent sources describe something new: a September 2025 release by a traceability vendor names a regulatory authority for pharmacy, laboratories and medicines as manager of the National Drug Catalogue, the single repository for medicine data, and reports that the Minister of Public Health signed the national track-and-trace mandate into force on 19 September 2025; a consultancy note dates the instruments to a ministerial despatch of that day, opens platform registration in October 2025, sets a master-data deadline of 15 November 2025 and reports the regulation in force from March 2026, after which unregistered actors may not manufacture, import, distribute or dispense. We record those claims as reported, not as established. We found no law or decree creating the new authority, no website for it, and no confirmation that the March 2026 deadline took effect; sources give two different expansions of its acronym, so we print none. Two further facts frame the picture. First, the November 2025 elections were followed on 26 November by a military takeover, a transitional council held a constitutional referendum on 30 August 2026 that the opposition boycotted, and a general election is signalled for December 2026; a supplier should expect administrative timelines to move. Second, the regional harmonisation layer is membership rather than participation: all fifteen ECOWAS states, Guinea-Bissau among them, endorse the ECOWAS medicines regulatory harmonisation initiative led by the West African Health Organisation, but only seven authorities — Burkina Faso, Côte d'Ivoire, Ghana, Nigeria, Senegal, Sierra Leone and Togo — actively take part in joint assessments, and Guinea-Bissau is not one of them. A dossier built to the harmonised ECOWAS CTD, which is the format the UEMOA regulation aligns to, is nonetheless the file most likely to be accepted without rework. Quality Systems Behind Every Injectable Supplied to Guinea-Bissau For a sterile injectable the evidence any assessor or inspector expects is the same: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A and Q1B stability data appropriate to a hot, humid tropical climate with a long rainy season rather than data extrapolated from a temperate one. Because the UEMOA regulation routes every file through an expert committee that may draw on assessors from other member states, the file should read well in French as well as in Portuguese, and the quality module should be written for an assessor who has not visited the site. The international layers are quickly stated. Neither Guinea-Bissau nor India appears on the list of PIC/S participating authorities. Guinea-Bissau does not appear on the WHO's August 2026 list of authorities at maturity level 3 or 4, and India's CDSCO appears on it for vaccines only, so any generic clause admitting products approved by a level-3 authority would not carry a small-molecule injectable from India; we found no such clause in Guinea-Bissau, and note it only so that a buyer reads any future reliance provision with the scope column of the WHO list in hand. On the African Union's treaty status list of 22 May 2026, Guinea-Bissau has neither signed nor ratified the treaty establishing the African Medicines Agency. Import control, as the harmonisation page describes it, is authorisation plus port-of-entry inspection and sampling, with no origin discrimination stated; we found no rule that singles out India at the border and do not assert that none exists. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Guinea-Bissau for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries, several of them in French- and Portuguese-speaking West Africa. We build dossiers in CTD and ACTD format, which is exactly the five-module structure Règlement 04/2020 prescribes, and we supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course. Because the regulation requires the authorisation holder to be located or represented in the country and the private channel runs through licensed wholesale importers, our standard route is to register through, or in partnership with, a licensed Bissau-Guinean importer, and to price with the union's fee preference for regional producers and the Article 12 price and market-saturation criteria in view. The bilateral relationship is real but thinly documented. The Ministry of External Affairs publishes bilateral briefs on Guinea-Bissau, but the files returned nothing readable to us, so we quote no trade figure from them; search summaries of the brief describe India's exports as including iron and steel, rice, pharmaceuticals, construction material and textiles, and India as the principal buyer of Guinea-Bissau's raw cashew crop, with two Indian lines of credit for agriculture and rural electrification. We report the mention of pharmaceuticals as reported, not as read. UN Comtrade returned nothing usable for the pharmaceutical trade between the two countries, so no figure is published here. We found no health memorandum between the two governments and no regulator-to-regulator agreement. India's duty-free tariff preference for least-developed countries is sometimes cited in this context; it governs goods entering India and does nothing for an Indian injectable entering Bissau. Where the money is: Guinea-Bissau has 2.25 million people, gross national income per capita of USD 1,090 in 2025, current health expenditure of about USD 82 per person and 8.8% of GDP in 2023, and life expectancy of 64.3 years. Out-of-pocket payments were 61.6% of health expenditure in 2023, so a private retail channel exists, served in 2023 by four licensed wholesale importers who reported operating well below licensed capacity and difficulty importing overland through Senegal; total medicine imports are reported at only about USD 4 million a year. The larger flows are donor-funded: UNDP is principal recipient of the Global Fund malaria grant of thirty million euros for 2024 to 2026 and rehabilitated the CECOME central warehouse, the Ministry of Public Health manages a second grant of the same size for HIV and tuberculosis, and UNICEF delivers vaccines and World Bank-financed consignments. CECOME, the Central de Compra de Medicamentos Essenciais, announced in February 2025 that it would resume purchasing essential generics after being unable to buy its own stock since about 2014; whether it now tenders internationally we could not confirm. Tuberculosis incidence was 176 per 100,000 in 2024, HIV prevalence among adults 2.2%, and malaria incidence 110 per 1,000 people at risk — the last being the largest driver of demand for injectable artesunate and other sterile anti-infectives. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Guinea-Bissau's list of recognised regulatory authorities? No list was found. Neither a national list nor a UEMOA-level list of reference, reliance or stringent authorities exists in readable form; the only reliance clause in Règlement 04/2020/CM/UEMOA allows reliance on another member state's authority, inside the union. The WHO's August 2026 maturity list does not include Guinea-Bissau and places India's CDSCO at level 3 for vaccines only. We neither claim nor deny that CDSCO approval carries weight in Bissau, and we found no rule that singles out Indian-origin medicines at the border. What law governs medicine registration in Guinea-Bissau? Règlement 04/2020/CM/UEMOA of 28 September 2020, the West African Economic and Monetary Union regulation on marketing authorisation procedures, which abrogated Règlement 06/2010 and binds all eight member states. It prescribes a five-module CTD, a five-year authorisation renewable on application lodged 120 days before expiry, review by an expert committee and a national medicines commission, an authorisation holder located or represented in the country, and a base fee reduced by half for medicines manufactured within the union. National fees, timelines and sample rules were not found. Who is the regulator now? In transition. The 2011 WHO profile names the Directorate of Pharmaceutical, Laboratory and Drug Services under the Ministry of Public Health, with no website. Vendor and consultancy sources from September and October 2025 name a new regulatory authority for pharmacy, laboratories and medicines that manages the National Drug Catalogue and a track-and-trace mandate signed on 19 September 2025, reported to take effect in March 2026. We could not locate the instrument that created it and do not confirm that the deadline was met. Who buys injectables in Guinea-Bissau? Mostly donor channels: UNDP as principal recipient of the Global Fund malaria grant, the Ministry of Public Health for the HIV and tuberculosis grant, and UNICEF for vaccines and World Bank-financed consignments. CECOME, the state purchasing centre, announced in February 2025 that it would resume buying essential generics. Four licensed private wholesale importers served the retail channel in 2023, where out-of-pocket payments are 61.6% of health spending. Public tenders are published as annual lists by the Direção Geral dos Concursos Públicos rather than through a transactional portal. Does Farbe Firma have experience with UEMOA and ECOWAS markets? Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, several in French- and Portuguese-speaking West Africa. We prepare dossiers in CTD and ACTD format to the harmonised ECOWAS structure, supply the WHO-format CPP, manufacturing licence and GMP certificate, and work through licensed local importers. Write to director@farbefirma.org with the product list and we will map the file to the UEMOA procedure. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 4, 2026 TL;DR: Lesotho answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with no list at all, and with a regulator that is still being built. The Lesotho Medicines and Medical Devices Control Authority Act of 2023 was brought into operation on 1 March 2026, replacing the 2008 framework, and the new authority is reported to be awaiting its regulations; no medicines register, guideline library or reference-authority list could be found. The only clause that touches India is the WHO's maturity list, on which India's CDSCO is level 3 for vaccines only, and Lesotho itself is not listed. Lesotho is a SADC member but not among the nine active ZaZiBoNa participants. The commercial gate is the National Drug Service Organisation in Mafeteng, a Ministry of Health trading body that approves suppliers before they may bid and now also procures for the church-run CHAL network. Out-of-pocket spending is 13% of health expenditure, tuberculosis incidence is 548 per 100,000, and India's own brief names pharmaceuticals as its leading export to the country. Key Takeaways No list, and a law that is weeks old in practice. The 2023 Act commenced on 1 March 2026 and is reported to await implementing regulations; the Act text itself could not be downloaded, so we describe it only from secondary summaries. We do not print an acronym for the new authority because sources disagree on its name, and we do not assert that a medicines register exists or that any product is currently registered. The generic clause would not admit an Indian injectable. Lesotho is absent from the WHO's August 2026 list of authorities at maturity level 3 or 4, and CDSCO is on that list for vaccines only. Any Lesotho or regional rule that relies on maturity level 3 would therefore cover an Indian vaccine but not a small-molecule sterile injectable. Lesotho attended the 2025 Indian Pharmacopoeia policymakers' visit, which is a positive signal, not a rule. The regional layer is membership without active participation. Lesotho is one of the sixteen SADC states and is a ZaZiBoNa member in name, but it is not among the nine authorities that actively assess dossiers jointly; it attended the June 2025 SADC GMP-inspection meeting. It is a member of the Southern African Customs Union, which means most goods physically clear through South Africa and the trade statistics reflect that. The buyer is NDSO, and it approves suppliers first. The National Drug Service Organisation in Mafeteng procures, stores and distributes for government and other health institutions, sources from suppliers with GMP accreditation, and requires a supplier to apply for approval before bidding on its tenders and requests for quotation. The Ministry of Health has taken over medicines procurement for the CHAL church-hospital network, so that demand now flows through the same channel. Introduction: Why Lesotho Demands a Premium Injectable Manufacturer in Lesotho Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Lesotho is the first market where the question arrives before the regulator has finished being created. The framework in force for most of the past two decades was the Medicines and Medical Devices Control Act of 2008; the WHO-derived country profile compiled for the African Medicines Regulatory Harmonisation programme recorded that as of 2008 there were no legal provisions requiring marketing authorisation for all pharmaceutical products on the market, no legal basis for a pharmacovigilance centre, and inspections that were lawful but not required. That is the baseline. The replacement, the Lesotho Medicines and Medical Devices Control Authority Act of 2023, was brought into operation by the Minister of Health on 1 March 2026, and the authority it establishes is reported to be awaiting its regulations, with the Ministry's budget for 2026 setting aside funds for the authority's offices. We could not download the Act's text, so everything we say about its content comes from secondary summaries: that no medicine or device may be sold, manufactured, distributed, imported or exported unless registered and unless the person is licensed by the Board, that registration turns on safety, quality and efficacy, and that quality testing is to be done at the national quality-control laboratory or an accredited one. We do not print an acronym for the new authority because the sources we read call it three different things. No medicines register, no guideline library, no application portal and no list of reference or reliance authorities could be found, and we do not fill that gap with the plausible theory that Lesotho relies on South African registration, because we could not verify it. The answer to the standing question is therefore no list, with the regulator in transition, and a premium injectable manufacturer in Lesotho is one whose file is complete enough to be assessed under whichever regulations arrive. What Sets a World-Class Injectable Manufacturer in Lesotho Apart Because the national guideline does not yet exist in readable form, the practical standard is set by the regional and international layers. Lesotho is one of the sixteen SADC member states and is counted as a ZaZiBoNa member, but ZaZiBoNa distinguishes its nine actively participating authorities — Zambia, Zimbabwe, Botswana, Namibia, Tanzania, the Democratic Republic of the Congo, Malawi, Mozambique and South Africa — from the non-active members, and Lesotho is in the second group; it did attend the SADC good-manufacturing-practice inspection meeting of June 2025. The consequence for a supplier is that a dossier prepared to the ZaZiBoNa common standard, in CTD format with a WHO-format certificate of a pharmaceutical product and a current GMP certificate, is the file most likely to be accepted without rework whatever the new regulations say, because it is the file the neighbouring assessors already work from. The one clause that reaches India is the WHO's maturity list, and it deserves precision. Lesotho does not appear on the WHO's August 2026 list of authorities operating at maturity level 3 or 4, and its actual benchmarked level is not published. India's CDSCO does appear, at level 3 for vaccines only, and so does South Africa's SAHPRA, also for vaccines only. A rule that admits products approved by a level-3 authority would therefore cover an Indian vaccine and would not cover a small-molecule sterile injectable from India, or, for that matter, one registered in South Africa. We have found no such rule in Lesotho, and we state this only so that a buyer reads any future reliance provision with the scope column of the WHO list in hand. Lesotho's deposit of its ratification of the African Medicines Agency treaty is recorded for 1 September as the twenty-third state, with the year not confirmed in the text we read; its PIC/S and AVAREF status we could not establish. We found no rule that singles out India at the border, and we do not assert that none exists. Quality Systems Behind Every Injectable Supplied to Lesotho For a sterile injectable the evidence any assessor or inspector expects is the same: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A and Q1B stability data appropriate to a highland climate with cold winters and strong sunlight rather than data extrapolated from elsewhere. The 2023 Act is reported to route quality testing to the national quality-control laboratory or an accredited one, so the certificate of analysis for each batch should be written to be reproduced, with methods that a modest laboratory can run. Lesotho's membership of the Southern African Customs Union with South Africa, Botswana, Namibia and Eswatini shapes the logistics and the statistics. Most consignments physically enter through South Africa and clear under the common external tariff, which is why the trade figures below disagree by direction and why cold-chain and temperature-excursion records should cover the road leg from Durban or Johannesburg as carefully as the air leg from India. National Drug Service Organisation states that it sources from suppliers with relevant GMP accreditation, and a WHO-GMP certificate with a recent inspection date is the document that answers that requirement. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Lesotho for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format, the structure the ZaZiBoNa assessors and every SADC authority we have dealt with work from, so that the file is ready for whichever regulations Lesotho's new authority issues, and we supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course. For a market where the regulator is being built, the more useful guarantee is a commercial one: complete supplier-approval documentation for NDSO, batch certificates of analysis written to be reproduced, and stability data for the climate the product will live in. The bilateral relationship is small and pharmaceuticals lead it. India's Ministry of External Affairs brief of April 2026 records Indian exports to Lesotho of USD 10.30 million in 2024–25 against imports of USD 0.98 million, describes the trade as minimal, and names pharmaceuticals first among the major items India exports, ahead of rubber, plastics and machinery. Lesotho has accepted India's duty-free tariff preference scheme. In June 2025 Lesotho's Director of Clinical Services and the head of its medicines regulatory body visited India for the second policymakers' programme on the Indian Pharmacopoeia, and India's Minister of State made the first ministerial visit to Lesotho in a decade in July 2025. The only health memorandum the brief names is between Apollo Hospitals and the Ministry of Health; there is no regulator-to-regulator agreement. UN Comtrade tells two stories that we report separately and do not average: India reports pharmaceutical exports to Lesotho of USD 13.05 million in 2022, 5.60 million in 2023, 6.41 million in 2024 and 7.93 million in 2025, while Lesotho reports imports from India of 17.29 million, 7.80 million and 12.94 million for 2022 to 2024 — higher every year, consistent with goods that transit South Africa. Where the money is: Lesotho has 2.36 million people, gross national income per capita of USD 1,280 in 2025, current health expenditure of about USD 123 per person and 12.6% of GDP in 2023, an unusually high share, and life expectancy of 57.8 years. Out-of-pocket payments were 13.2% of health expenditure in 2023, so the market is public and donor-financed rather than retail, and the National Drug Service Organisation in Mafeteng — the Ministry of Health's procurement, storage and distribution body, which publishes tenders and requests for quotation and requires suppliers to apply for approval before bidding — is the commercial gate; a SADC-funded electronic tendering portal for NDSO is in development. The Christian Health Association of Lesotho runs eight hospitals and 71 health centres and is reported to deliver more than 40% of care, and after shortages at its facilities the Ministry has taken over medicines procurement for them, so that demand now flows through NDSO too. Tuberculosis incidence was 548 per 100,000 in 2024, among the highest in the world though falling from 659 in 2018, and HIV prevalence among adults 17.1%; both sustain a steady requirement for sterile anti-infectives that a supplier can plan production around. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Lesotho's list of recognised regulatory authorities? No list was found. Lesotho's regulator is being re-established under the 2023 Act, in operation since 1 March 2026 and reported to await its regulations, and no reference-authority list, medicines register or guideline library could be located. The only clause that touches India is the WHO maturity list, on which CDSCO is level 3 for vaccines only and Lesotho is absent, so a level-3 rule would not admit an Indian small-molecule injectable. We neither claim nor deny that CDSCO would be recognised. What law governs medicine registration in Lesotho now? The Lesotho Medicines and Medical Devices Control Authority Act of 2023, brought into operation on 1 March 2026, replacing the 2008 framework. Secondary summaries describe a registration requirement for medicines and devices, licensing of persons by the Board, and quality testing at the national or an accredited laboratory; the Act text itself could not be downloaded and the implementing regulations are reported as pending, so format, language, fees, timelines and validity are not yet published. Does Lesotho take part in ZaZiBoNa? As a non-active member. All sixteen SADC states are counted as ZaZiBoNa members, but only nine — Zambia, Zimbabwe, Botswana, Namibia, Tanzania, the DRC, Malawi, Mozambique and South Africa — actively assess dossiers jointly, and Lesotho is not among them. It attended the June 2025 SADC GMP-inspection meeting. A dossier prepared to the ZaZiBoNa common CTD standard is nonetheless the safest file to bring. Who buys injectables in Lesotho? The National Drug Service Organisation, NDSO, in Mafeteng, the Ministry of Health's procurement, storage and distribution body, which sources from GMP-accredited suppliers, publishes tenders and requests for quotation, and requires suppliers to apply for approval before bidding. The Ministry has taken over medicines procurement for the CHAL church-hospital network, so that demand also flows through NDSO. Out-of-pocket spending is 13.2% of health expenditure, so the private retail channel is small. Does Farbe Firma have experience with SADC and SACU markets? Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, several of them in southern Africa. We prepare dossiers in CTD and ACTD format, supply the WHO-format CPP, manufacturing licence and GMP certificate, and can document the cold chain from India through South Africa. Write to director@farbefirma.org with the product list and we will prepare the NDSO supplier-approval file. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 4, 2026 TL;DR: Botswana answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with a reliance pathway that visibly exists and a list we could not read. The Botswana Medicines Regulatory Authority, BoMRA, created under the Medicines and Related Substances Act of 2013, opened a reliance-based expedited registration window for veterinary products in May 2026 and says it is building a BoMRA Reliance Framework aligned to the continental framework of AUDA-NEPAD; its guideline and fee libraries sit behind a document plugin that returned no text, so whether India's CDSCO is named, excluded or covered by a general clause is unknown in both directions. What is published is the procedure — screening with a fee, then application fees, samples and a signed form, scientific evaluation, a query letter and a Registration Committee decision — and a five-year marketing authorisation. Botswana is a founding member of the ZaZiBoNa work-sharing initiative. The commercial gate is the Central Medical Stores of the Ministry of Health, buying through the national e-tender portal, in a country that declared a public health emergency over medicine shortages in August 2025 and whose Health Minister travelled to Ahmedabad in 2022 to negotiate with Indian suppliers. Key Takeaways A reliance route exists; its reference list is unread. BoMRA's expedited reliance-based registration was opened for veterinary medicines from 1 May to 31 July 2026 and the authority states that a BoMRA Reliance Framework aligned to the AUDA-NEPAD Continental Reliance Framework is in development. We could not read the guideline or fee documents, so we do not say whether the human-medicines route is open or whether India is on any list. The published procedure is sequential and fee-gated. A full dossier goes in with a screening fee for a completeness check; after screening the applicant is told to pay the application fee, submit samples and a signed form; scientific evaluation follows, then a query letter with a deadline and a decision by the Registration Committee. The marketing authorisation runs for five years and must be renewed. Timelines are set out in a service-standards document we could not retrieve. The regional layer is real. Botswana co-founded ZaZiBoNa with Zambia, Zimbabwe and Namibia in 2013, the SADC work-sharing initiative for joint dossier assessment. Neither Botswana nor India is a PIC/S participating authority, and BoMRA is not on the WHO's August 2026 list of maturity-level-3 authorities, having completed an assisted self-benchmarking exercise in August 2025. The buyer is the State, and the State has been short of medicines. Out-of-pocket spending is only 4.3% of health expenditure, so Central Medical Stores tenders on the national e-tender portal are the market. Botswana declared a public health emergency over medicine shortages in August 2025, with essential-medicine availability reported at 17% that month and 36% by October, and the Health Minister led a delegation to Ahmedabad and New Delhi in late 2022 to negotiate with Indian suppliers. Introduction: Why Botswana Demands a Premium Injectable Manufacturer in Botswana Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Botswana gives an answer we have met before in a new form. The regulator is the Botswana Medicines Regulatory Authority, BoMRA, a body corporate under the Medicines and Related Substances Act of 2013 that regulates human and veterinary medicines, medical devices and cosmetics. BoMRA plainly operates a reliance concept: in 2026 it opened a reliance-based expedited registration window for veterinary medicinal products, from 1 May to 31 July, and it states that a BoMRA Reliance Framework aligned to the AUDA-NEPAD Continental Reliance Framework is being developed. A reliance framework implies a list of authorities whose work is relied on. We went looking for that list and could not read it: the authority's guidelines and fee schedules are published through a document-download plugin that returned no titles and no text to us, and no page of the site we could read names a reference authority. So we do not say that India is on a Botswana list, and we do not say it is absent; the honest position is unknown in both directions. There is one risk worth stating in advance. Continental reliance frameworks often reach for the WHO's Global Benchmarking Tool and admit authorities at maturity level 3 or above. On the WHO's August 2026 list, India's CDSCO is benchmarked at level 3 for vaccines only, not for medicines, so a clause of that shape would not admit a small-molecule sterile injectable from India. That is a hypothesis about a document we have not read, not a finding, and we flag it so that a buyer can check it against the framework when it is published. What is not in doubt is the shape of the market a premium injectable manufacturer in Botswana must serve: a public system that finances almost all medicine and that spent 2025 in a declared shortage emergency. What Sets a World-Class Injectable Manufacturer in Botswana Apart The published procedure is more sequential than most in the region, and the sequence matters for planning. A full product dossier is submitted together with a screening fee; screening is a completeness check, not an assessment. Once the dossier passes screening the applicant is advised to pay the application fees, to submit product samples and to lodge a signed application form. Scientific evaluation follows, then a query letter with a deadline for the response, and finally a decision by the Registration Committee. BoMRA refers applicants to its service standards for timelines; we could not retrieve that document, so we quote no number of days. The authority's own answer to how long registration takes is that it can take several months. A marketing authorisation is valid for five years, after which a renewal application is required, and variations are handled as a separate procedure. There is also an exemption route for essential unregistered products urgently needed for public health, which became relevant during the 2025 shortage. Several things a supplier would normally settle from the guidelines we cannot settle here. Whether the common technical document is mandatory at first submission, whether a local applicant, agent or pharmacovigilance contact must be appointed, how many samples are required and in what language the file is examined are all questions the guideline library would answer and that we were unable to read. The screening fee is reported at 500 pula and an annual retention fee falls due by 31 March; we have not seen the instrument that sets registration, renewal or inspection fees and quote none of those. What is clear from BoMRA's public pages is that the authority inspects for good manufacturing, distribution and pharmacy practice along the supply chain and that it will inspect a manufacturing or storage establishment at a prescribed fee, so a foreign site should expect to be assessed rather than simply certified. BoMRA also registers distributors separately, which is the route a Botswana importer or wholesaler must follow before it can carry a product. Quality Systems Behind Every Injectable Supplied to Botswana For a sterile injectable the evidence an assessor and an inspector expect is the same everywhere: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A and Q1B stability data appropriate to a hot, dry climate with wide temperature swings rather than data extrapolated from a temperate one. Because BoMRA reserves the right to inspect the establishment, the batch records, deviation logs and change controls behind those results should be ready to be walked through, not just summarised. The regional layer sets the wider expectation. Botswana co-founded ZaZiBoNa in October 2013 with Zambia, Zimbabwe and Namibia, the SADC work-sharing initiative under which assessors from participating authorities review dossiers jointly and inspect sites together; a file prepared to ZaZiBoNa's common standard therefore travels. Neither Botswana nor India appears on the PIC/S list of participating authorities, and BoMRA is not on the WHO's August 2026 list of authorities at maturity level 3 or 4, having completed a five-day assisted self-benchmarking exercise with the WHO in August 2025. Botswana's ratification of the African Medicines Agency treaty is reported for February 2025, but the agency's own page does not name the country in readable text, so we record the report as unconfirmed. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Botswana for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format, which is the structure ZaZiBoNa assessments and every SADC authority we have dealt with work from, and we can give the written commitment to a full CTD file that BoMRA material refers to without hesitation because the file already exists in that form. We supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course, and we treat a request for a site inspection as a normal part of doing business rather than an obstacle. Where the reliance framework, when published, names authorities that do not include India, our answer is a complete stand-alone file assessed on its merits, which is the route we take in most of the markets in this series. The bilateral relationship is substantial and pharmaceuticals are already part of it. The Indian High Commission's brief of January 2026 records bilateral trade of USD 506.34 million in 2024–25, with Indian exports of USD 173.44 million and imports of USD 332.90 million, the imbalance reflecting Botswana's diamond exports, and it lists pharmaceuticals explicitly among India's exports to Botswana and names pharmaceuticals and medical devices as an identified opportunity for expansion. The single most useful commercial fact for a Gujarat manufacturer is that Botswana's Minister of Health led a five-member delegation to Ahmedabad and New Delhi from 28 November to 1 December 2022 for negotiations with Indian medical suppliers. We do not quote a UN Comtrade figure for pharmaceutical trade because the database returned nothing usable to us for this pair, and no health memorandum or regulator-to-regulator agreement between CDSCO and BoMRA is mentioned in the brief. Where the money is: Botswana has 2.56 million people, gross national income per capita of USD 7,390 in 2025, current health expenditure of about USD 490 per person and 6.3% of GDP in 2023, and life expectancy of 69.3 years. Out-of-pocket payments were 4.3% of health expenditure in 2023, among the lowest shares anywhere, so the State pays for medicine and the Central Medical Stores of the Ministry of Health, procuring, storing and distributing for public facilities and tendering on the national e-tender portal, is the commercial gate; private wholesalers, pharmacies and the BPOMAS and BOMAID medical-aid schemes serve the rest. HIV prevalence among adults was 15.7% and tuberculosis incidence 143 per 100,000 in 2024, both falling, both sustaining demand for sterile anti-infectives. In August 2025 the government declared a public health emergency over medicine shortages, attributed to weak diamond revenue and the loss of donor funding, with essential-medicine availability reported at 17% that month and 36% by early October and about USD 75 million owed to private suppliers; a supplier entering now should price and contract with that payment history in view, and should expect the shortage-driven exemption route and emergency procurement to coexist with the normal one. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Botswana's list of recognised regulatory authorities? Unknown in both directions. BoMRA operates a reliance concept — a reliance-based expedited window was opened for veterinary medicines in May 2026 and a BoMRA Reliance Framework aligned to the AUDA-NEPAD Continental Reliance Framework is described as under development — but the guideline and fee documents that would carry a reference list are published through a download plugin that returned no text to us, and no readable page names a reference authority. We therefore neither claim nor deny that CDSCO is recognised. Note that on the WHO's August 2026 list CDSCO is benchmarked at maturity level 3 for vaccines only, so a generic level-3 clause would not cover a small-molecule injectable. What does the BoMRA registration procedure look like? A full dossier is submitted with a screening fee for a completeness check; after screening the applicant pays the application fees and submits samples and a signed application form; scientific evaluation follows, then a query letter with a response deadline, and the Registration Committee decides. The marketing authorisation is valid for five years and must then be renewed. Timelines are set in a service-standards document we could not retrieve, and BoMRA's own guidance says registration can take several months. Which fees and dossier rules apply? The screening fee is reported at 500 pula and an annual retention fee falls due by 31 March. We have not seen the instrument that sets registration, renewal or GMP-inspection fees, so we quote none, and we could not read the guideline that would settle CTD format, local applicant, sample and language requirements. BoMRA states that it inspects establishments along the supply chain at a prescribed fee and registers distributors separately. Who buys injectables in Botswana? Overwhelmingly the State. Out-of-pocket spending was 4.3% of health expenditure in 2023, so the Central Medical Stores of the Ministry of Health, which procures, stores and distributes for public facilities and tenders on the national e-tender portal, is the commercial gate, with private wholesalers, pharmacies and medical-aid schemes such as BPOMAS and BOMAID serving the private sector. A public health emergency over medicine shortages was declared in August 2025 and about USD 75 million was reported owed to private suppliers, so payment terms deserve attention. Does Farbe Firma have experience with SADC and ZaZiBoNa-style markets? Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, several of them in the SADC region. We prepare dossiers in CTD and ACTD format, supply the WHO-format CPP, manufacturing licence and GMP certificate, and are ready for a site inspection. Write to director@farbefirma.org with the product list and we will map the file to BoMRA's sequence. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 3, 2026 TL;DR: Gabon answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with no list at all. The new Agence Nationale du Médicament et des Autres Produits de Santé, created by ordinance in October 2023 and given its statutes in January 2025, publishes a single dossier checklist for the Autorisation de Mise sur le Marché Gabonais and no reliance or abridged pathway; its guidelines page is empty and none of its thirty legal texts concerns recognition of foreign authorities. The CEMAC harmonisation regulation exists and the regional body OCEAC runs pilot joint evaluations, but no common authorisation is in force. The route is therefore the national one: a French-language CTD on USB, a GMP certificate under three years old for the finished-product site and for every active-ingredient site, fifty samples, a declared ex-factory price in CFA francs, a fee of 500,000 FCFA for an imported medicine, and a five-year authorisation. The commercial gate is the Office Pharmaceutique National, the state central purchasing body that supplies public hospitals and also private wholesalers, and the CNAMGS insurance fund, whose reimbursement rules were rewritten in 2025 and are still being contested. Key Takeaways No reliance list exists, so the origin-country file must be complete. The ANMAPS checklist asks for a copy of the country-of-origin authorisation with a certified French translation, a WHO-format certificate of a pharmaceutical product, the list of countries where the product is registered and, where it applies, WHO prequalification. Nothing conditions acceptance on the origin regulator being on a list, because there is no list; whether CDSCO would be treated as a reference authority is unknown in both directions. The dossier is French and electronic. Module 1 on paper and USB, Modules 2 to 5 in CTD format on USB only, the summary of product characteristics in French in editable form, a GMP certificate less than three years old for the finished-product manufacturer and each active-ingredient manufacturer, the manufacturing licence, the CVs of the heads of production and quality control, fifty commercial-pack samples with certificates of analysis, and an attestation of the ex-factory wholesale price in CFA francs. The instruments and fees are published; the timeline is not. The AMMG is valid for five years and a temporary commercial authorisation for two; the fee order of the Ministry of Health sets 500,000 FCFA for registration of an imported medicine, 350,000 for renewal, 100,000 for a major variation and 250,000 for a temporary authorisation. No statutory review period is published anywhere we could read, and we state none. The buyer is the State's central purchasing body and the insurance fund. The Office Pharmaceutique National buys under the public procurement code and supplies public hospitals, national programmes and private wholesalers from four bulk warehouses and nine regional depots. CNAMGS reimbursement was reset in March 2025 to 80%, 90% and 100% by category, with generics favoured over branded products, and the new reimbursable list was contested and suspended within months. Out-of-pocket spending is 17.3% of health expenditure, low for the region. Introduction: Why Gabon Demands a Premium Injectable Manufacturer in Gabon Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Gabon is the clearest case yet of the answer being no list at any layer. The regulator is the Agence Nationale du Médicament et des Autres Produits de Santé, ANMAPS, an independent administrative authority under the Ministry of Health created by Ordinance No. 0004/PR/2023 of 24 October 2023, ratified by Law No. 006/2023 of 26 January 2024 and given its statutes by Decree No. 0091/PR/MS of 31 January 2025; it succeeds the former Direction du Médicament et de la Pharmacie and sits on the 2011 ordinance organising the pharmaceutical sector. Its website publishes one page on the registration of medicines, the homologation checklist for the Autorisation de Mise sur le Marché Gabonais, and that page contains no reliance route, no abridged procedure and no reference authorities. The guidelines section of the site is empty. Of the thirty legal texts the agency lists, only the order on variations and the order on fees concern the authorisation procedure, and neither names a foreign authority. The regional layer does not supply a list either. Gabon belongs to CEMAC, and Community Regulation No. 05/13 on the harmonised registration of medicines exists; we could not read its text. The regional health body OCEAC runs joint evaluation workshops under it — the Brazzaville session of December 2025 assessed fewer than fifteen dossiers selected through a call in August — and those are a pilot, not a route a company can plan around, so the national AMMG remains the operative gate. What the checklist does ask for is the origin-country authorisation with a certified French translation, a WHO-model certificate of a pharmaceutical product, the list of countries where the product is registered, and WHO prequalification where it applies. We therefore do not say that India is on or off any Gabonese list, because there is none; we say that a premium injectable manufacturer in Gabon is one whose Indian authorisation, CPP and GMP evidence are complete enough to stand on their own in French. What Sets a World-Class Injectable Manufacturer in Gabon Apart The dossier is French-language and electronic, and that settles more than it seems. The application is addressed to the Minister of Health through the Director-General of ANMAPS and signed by a responsible pharmacist; Module 1 goes in on paper and on USB, Modules 2 to 5 in CTD format on USB only, with the summary of product characteristics in French in an editable file and Module 5 carrying the biowaiver justification where a generic claims one. The checklist requires the certificate of opening of a pharmaceutical establishment for the authorisation holder, for the operating company and for the finished-product manufacturer, and a description of the commercial links between them. Whether the operating company must itself be established in Gabon is governed by an order on pharmaceutical establishments that we located but did not read, so we neither assert nor deny it; commercially, a Gabonese responsible pharmacist and importer are how the file is signed and how the product is sold. Fifty commercial-pack samples with certificates of analysis accompany a registration and thirty a renewal, and an attestation of the ex-factory wholesale price in CFA francs is part of the file, which means the price is declared before the product is authorised. The GMP requirement is stricter on paper than in many larger markets. The checklist wants a GMP certificate less than three years old for the finished-product manufacturer and for each manufacturer of an active ingredient, the manufacturing licence, the curricula vitae of the heads of production and quality control, and a copy of the notification of a favourable opinion for the laboratory visited — wording that implies an inspection step whose conditions and cost are not published, so we do not describe them. The instruments are clear: the AMMG is valid for five years and the temporary commercial authorisation, on the same dossier, for two. The fee order of the Ministry of Health, which we read as a scanned document, sets 500,000 FCFA for registration of an imported medicine against 300,000 for a locally made one, 350,000 for renewal of an imported product, 100,000 for a major and 50,000 for a minor variation, and 250,000 for a temporary authorisation. What is not published anywhere we could find is a review timeline, and the figures that circulate on consultancy sites are not something we repeat. The process is described as submission, expert analysis, commission, authorisation, and a supplier should plan for the commission calendar rather than a statutory clock. Quality Systems Behind Every Injectable Supplied to Gabon For a sterile injectable the evidence behind the GMP certificate is what will be tested if the laboratory-visit step is exercised: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A stability generated for a hot and humid climate rather than extrapolated. Because the checklist also asks for the active-ingredient manufacturer's GMP certificate, the supplier must be able to produce its API supplier's certificate, under three years old, alongside its own — a detail that trips up manufacturers who treat the API file as somebody else's. Two further facts frame the file. Gabon does not appear on the WHO's August 2026 list of authorities operating at maturity level 3 or 4, which tells you only that it is not listed, not what its benchmarked level is; and it ratified the African Medicines Agency treaty in October 2021 as the fourteenth state to do so, while neither Gabon nor India is a PIC/S participating authority. ANMAPS announced ISO 9001 certification of its own management system in January 2026 and has been receiving evaluator training on bioequivalence and biosimilar dossiers through a French cooperation programme; a young agency building its assessment capacity is one that will ask more questions, not fewer, and the French-language quality of the answers will matter. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Gabon for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format and we are used to producing them in French for francophone Africa: Module 1 on paper and USB, Modules 2 to 5 electronic, the summary of product characteristics in editable French, the Indian authorisation with a certified translation, the WHO-format CPP, our own GMP certificate and our active-ingredient suppliers' certificates within three years, fifty samples with certificates of analysis and the ex-factory price attestation in CFA francs. Our analytical package of HPLC, GC, LAL, Karl Fischer and ICH Q1A/Q1B stability is written so that an expert analysis has nothing to return, and we say plainly that Gabon offers no reliance shortcut and that a complete national file is the whole strategy. The bilateral relationship is broad and the pharmaceutical trade is small but growing. India's Ministry of External Affairs brief of February 2025 records joint commission and foreign-service training agreements and an industry memorandum, and Gabon joined the Commonwealth in June 2022; pharmaceuticals were about USD 1.6 million and the sixth-ranked Indian export in 2023–24, far behind Gabon's mineral fuels, ores and timber flowing the other way, and we found no health or pharmaceutical memorandum and no cooperation between ANMAPS and CDSCO. UN Comtrade puts India-reported pharmaceutical exports to Gabon at USD 2.33 million in 2022, USD 2.12 million in 2023, USD 3.48 million in 2024 and USD 3.75 million in 2025, while Gabon reports imports of pharmaceutical products from India of USD 17.51 million in 2022 and USD 20.37 million in 2023. The two series differ by a factor of six to nine, which usually reflects goods of Indian origin arriving through European wholesalers; we report the gap and do not explain it. Where the money is: Gabon has 2.59 million people, gross national income per capita of USD 8,090 in 2025 — an upper-middle-income figure — current health expenditure of about USD 253 per person and 3.1% of GDP in 2023, and life expectancy of 68.5 years. Out-of-pocket payments were 17.3% of health expenditure in 2023, which is low for the region and reflects the insurance fund. The Office Pharmaceutique National, a state company created in 1995 and reorganised by ordinance in 2021, is the national central purchasing body: it buys under the public procurement code through international and restricted tenders, negotiated contracts and quotations, manages stock on an enterprise system, holds four bulk warehouses and one for the HIV and TB programmes, and supplies nine regional depots twice a year. Its clients are the university, regional and district hospitals, the health centres and national programmes, and also private wholesalers, polyclinics and NGOs; whether it is the mandatory supplier to public hospitals is not something we verified from a legal text, and we found no tender notices published. The CNAMGS fund's reimbursement was reset by ministerial order in March 2025 to 80% for common illnesses, 90% for long-term conditions and 100% for pregnant women, with generics by international non-proprietary name reimbursed at those rates and branded products at half; the accompanying list of reimbursable products was contested by pharmacies and suspended, and a ministerial meeting in November 2025 convened the fund, ANMAPS and the OPN to rebuild it. Tuberculosis incidence is high at 371 per 100,000, and the injectable demand is the general hospital formulary — antibiotics, anaesthetics, emergency, maternal and oncology medicines. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Gabon's list of recognised regulatory authorities? There is no list. The ANMAPS registration checklist contains no reliance or abridged pathway and names no reference authorities; its guidelines page is empty and none of its thirty legal texts concerns recognition of foreign regulators. The CEMAC harmonisation regulation exists but no common authorisation is in force. What Gabon asks for is the origin-country authorisation with a certified French translation, a WHO-format CPP, the list of countries where the product is registered and WHO prequalification where applicable. Whether CDSCO would be treated as a reference authority is unknown in both directions. What does a Gabonese marketing authorisation application require? An application to the Minister of Health through the ANMAPS Director-General, signed by a responsible pharmacist: Module 1 on paper and USB, Modules 2 to 5 in CTD format on USB in French, the SmPC in editable French, certificates of opening of a pharmaceutical establishment for the holder, the operating company and the manufacturer, a GMP certificate under three years old for the finished-product site and each API site, the manufacturing licence, CVs of the production and quality-control heads, fifty samples with certificates of analysis, the origin-country authorisation and CPP, and an ex-factory price attestation in CFA francs. What are the fees and how long is the authorisation valid? The Ministry of Health fee order sets 500,000 FCFA for registration of an imported medicine, 350,000 for renewal, 100,000 for a major variation, 50,000 for a minor one and 250,000 for a temporary commercial authorisation. The AMMG is valid for five years and the temporary authorisation for two. No statutory review period is published, and we do not state one. Can we use a CEMAC or regional registration to enter Gabon? Not in practice. Community Regulation No. 05/13 provides a harmonised framework and OCEAC runs pilot joint evaluations — the December 2025 session assessed fewer than fifteen dossiers — but no common CEMAC authorisation is in force and whether a joint evaluation leads automatically to a national AMMG is not established. Plan on the national procedure. How do we sell to the public sector in Gabon? Through the Office Pharmaceutique National, the state central purchasing body that procures under the public procurement code by international and restricted tenders, negotiated contracts and quotations, and supplies the public hospitals, health centres, national programmes and also private wholesalers from four bulk warehouses and nine regional depots. A Gabonese responsible pharmacist and importer are the practical partner. CNAMGS reimbursement rules were reset in 2025 and the reimbursable list is being rebuilt, so generic positioning by INN matters. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 3, 2026 TL;DR: The Gambia answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with three lists at three layers, and India appears on none of them by name. The Medicines Control Agency's 2023 reliance policy names the EMA, the EU and EEA authorities, the MHRA, the US FDA, PMDA, Swissmedic, Health Canada, the TGA, WHO prequalification, AVAREF, ECOWAS and PIC/S, plus any authority the WHO has benchmarked at maturity level 3 or above; India's CDSCO holds that level for vaccines only, so a small-molecule injectable cannot use it. The 2025 reliance guideline works from the WHO-Listed Authorities list, and the June 2026 listing guideline names forty stringent-authority countries, from Australia to the United States, without India. The practical consequence is a full 180-day review rather than the 90-day abridged one, a local representative and a Gambia-resident pharmacovigilance person, and — uniquely for Indian exporters — a pre-shipment inspection and analysis certificate on every consignment. Out-of-pocket spending is a third of health expenditure and the public buyer is Central Medical Stores; on the MCA register roughly six in ten products are already made in India, which tells you the route works when it is walked properly. Key Takeaways Three lists, none with India. The MCA Reliance Policy of November 2023 lists recognised institutions by name and adds a general clause for authorities at WHO maturity level 3 or higher; CDSCO is benchmarked at level 3 for vaccines only. The June 2025 reliance guideline relies on the WHO-Listed Authorities list, AVAREF, ECOWAS/WAHO and WHO prequalification. The June 2026 listing guideline names forty stringent-authority countries; India is not among them. An Indian WHO-GMP injectable without an SRA authorisation or WHO prequalification takes the standard 180-day route. The registration mechanics are written down and workable. Applications go in the MCA CTD format, with WAHO, WHO, EU or ICH CTD variants accepted, in English, with one hard copy of Module 1 and the rest on USB, three commercial-pack samples with batch certificates of analysis, a manufacturing licence and GMP certificate, and evidence that the product is registered and marketed in its country of origin. A non-resident holder must appoint a local representative registered in The Gambia and a pharmacovigilance person resident there. The authorisation lasts five years and may be renewed once for three. India is singled out at the border. Since June 2023 every pharmaceutical consignment from India has needed a Clean Report of Inspection and Analysis issued through Quntrol Laboratories in Mumbai, with document review, physical inspection at loading, sampling and testing at an MCA-approved laboratory, a 90-day certificate validity and at least 60% shelf life remaining on arrival. We could not confirm how the regime is being enforced in 2026; a supplier should plan for it in full. The commercial gate is the State and the programmes. Current health expenditure was about USD 26 per person and 2.9% of GDP in 2023, out-of-pocket payments were 33.8% of it, Central Medical Stores procures for the public facilities through the GPPA portal, and Global Fund grants for malaria, HIV and TB run to 2026 and 2027. The National Health Insurance Scheme has expanded from 13 to 69 contracted facilities; its medicines benefit has not been published in a form we could read. Introduction: Why The Gambia Demands a Premium Injectable Manufacturer in The Gambia Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? The Gambia is the first market where the honest answer is three lists at three layers, each of which we read. The first is the Medicines Control Agency's Reliance Policy, version 3 of 15 November 2023, whose appendix of recognised institutions names the European Medicines Agency, the national authorities of the EU and EEA states, the MHRA, the US FDA, Japan's PMDA, Swissmedic, Health Canada, Australia's TGA, WHO prequalification, AVAREF, the ECOWAS and WAHO harmonisation programme and PIC/S, and then adds a general clause for any national authority the WHO has benchmarked at maturity level 3 or above. That clause is the only door through which India could enter, and on the WHO's August 2026 list CDSCO holds maturity level 3 for vaccines only. For a sterile small-molecule injectable the door is closed. The second layer is the Reliance Guideline MCA-GL-109, version 2 of 25 June 2025, with its annex of reference institutions: the WHO-Listed Authorities and the transitional list, AVAREF, the ECOWAS and WAHO regional mechanism and WHO prequalification, with partial reliance allowed for an active ingredient on the strength of a WHO certificate, a WHO prequalification confirmation or an EDQM certificate of suitability. The guideline also states that reliance on a decision which was itself based on reliance is not acceptable, which closes the indirect route through a third country. The third layer is the Listing Guideline MCA-GL-117 of 19 June 2026, made under the 2023 amendment to section 26 of the Medicines and Related Products Act, which names forty countries considered to have stringent regulatory authorities — Australia, the twenty-seven EU members, Iceland, Liechtenstein, Norway, Japan, Saudi Arabia, South Korea, Russia, Singapore, Switzerland, Turkey, the United Kingdom and the United States — and allows their approved products to be listed for import in ten working days without registration. India is not on it. What this means for a buyer is simple: a premium injectable manufacturer in The Gambia is one that registers the ordinary way, completely and on the first attempt. What Sets a World-Class Injectable Manufacturer in The Gambia Apart Start with the dossier, because the MCA has written it down more clearly than most agencies in the region. Registration Guideline MCA-GL-102, version 4, calls for the MCA common technical document and states that WAHO, WHO, EU and ICH CTD formats are accepted; a generic files Modules 1, 2 and 3 with the bioequivalence section of Module 5 where relevant, on application form MCA-F-112/01, with one hard copy of Module 1 and a complete electronic copy on USB. The language is English, with notarised translations of anything else. Three samples in commercial packs go in with signed batch certificates of analysis. The Module 1 checklist asks for evidence that the product is registered in its country of origin and a certificate from the competent authority there that it is marketed, with a WHO-format certificate of a pharmaceutical product listed among the certification documents as applicable; a manufacturing licence and a GMP certificate are mandatory for an imported product, and the agency reserves the right to inspect the site at a fee. The 2022 fees regulations, which we read from a scanned gazette and therefore quote with care, put registration of an imported medicine at USD 300, renewal at USD 300, and a GMP inspection outside West Africa at USD 7,000. The clock is statutory and realistic. The agency acknowledges an application within two weeks, the standard review is 180 days and the abridged review for products with a stringent-authority authorisation or WHO prequalification is 90 days, with the clock stopping while queries are outstanding. A marketing authorisation is valid for five years and, under section 30 of the Act, may be renewed once for three years, after which a fresh application is required; the renewal must be filed at least 90 days before expiry and a late renewal is treated as a new application. Two structural requirements shape the commercial arrangement. A holder that is not resident in The Gambia must appoint a local representative that is a legal entity registered there, although the agency may accept a regional representative resident elsewhere in West Africa, and appointing one does not relieve the holder of legal responsibility. And the holder must have a qualified person for pharmacovigilance resident in The Gambia and file a summary of its pharmacovigilance system. We did not read the Act itself, which exists online only as page images, nor the 2020 regulations, so every requirement above is as the MCA's own guidelines quote it. Quality Systems Behind Every Injectable Supplied to The Gambia For a sterile injectable the evidence the MCA will look for is the evidence any inspector expects: media-fill records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, and HPLC or GC assay and impurity methods validated to ICH standards, with ICH Q1A stability data generated for the hot and humid zone rather than extrapolated. Because the GMP certificate is mandatory and India is not a recognised authority under the reliance policy, the certificate carries less weight than the file behind it, and a supplier should have the site master file and the last inspection report ready for the day the MCA exercises its right to visit. The requirement that is unique to Indian suppliers deserves its own paragraph. Guidance MCA-G-113/04 of 15 June 2023, issued after the 2022 contaminated-syrup deaths, requires every pharmaceutical consignment from India to carry a Clean Report of Inspection and Analysis issued through Quntrol Laboratories in Mumbai. The exporter registers with the inspection body for a fee of INR 20,000, each shipment goes through a document check that includes the state licensing authority's product permission, the MCA registration certificate and a valid certificate of pharmaceutical product, a physical inspection at loading, and sampling and testing at an MCA-approved laboratory; injectables are analysed within about fifteen days, the certificate is valid for ninety days and the product must have at least sixty per cent of its shelf life remaining on arrival. The guidance is still listed on the agency's website; we could not establish how strictly it is applied in 2026 or what the per-shipment cost now is, and we will not guess. Plan for it in full and build the lead time into the supply contract. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in The Gambia for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format and we can present them in the MCA CTD layout the agency asks for, with the Module 1 certification pack — manufacturing licence, GMP certificate, WHO-format CPP, evidence of registration and marketing in India — assembled so that a 180-day review has nothing to send back. Our analytical package of HPLC, GC, LAL, Karl Fischer and ICH Q1A/Q1B stability is written to the standard a site inspection would test, and we are candid that no reliance shortcut is available to an Indian product in The Gambia without WHO prequalification. We also treat the pre-shipment regime as part of the delivery, not an obstacle to it. The bilateral relationship is substantial and the pharmaceutical trade is established. India's Ministry of External Affairs brief records bilateral trade of USD 175.79 million in 2022–23, with Indian exports of USD 122.60 million, and lists drugs and pharmaceuticals among the major export items without ranking them; a joint commission agreement was signed in November 2021, and we found no health or pharmaceutical memorandum and no cooperation agreement between CDSCO and the MCA. UN Comtrade puts India-reported exports of pharmaceutical products to The Gambia at USD 8.66 million in 2022, USD 6.41 million in 2023, USD 9.46 million in 2024 and USD 8.81 million in 2025, while The Gambia reports imports from India of USD 3.62 million, USD 2.23 million and USD 3.07 million for 2022 to 2024; the two series differ by a factor of two to three and we give both rather than an average. The MCA's own register, updated in August 2026, carries about 2,500 products, and on a keyword count roughly six in ten are manufactured in India — a fact that says the route works, and that the competition on it is Indian. Where the money is: The Gambia has 2.82 million people, gross national income per capita of USD 930 in 2025, current health expenditure of about USD 26 per person and 2.9% of GDP in 2023, and life expectancy of 66.1 years. Out-of-pocket payments were 33.8% of health expenditure in 2023, so the State and its partners are the larger buyer. The Directorate of National Pharmaceutical Services and Central Medical Stores procure and distribute for the public facilities, with tenders run under the Public Procurement Act 2022 on the GPPA portal, and the Global Fund's active grants — malaria to June 2027, HIV and TB to December 2026 — bring pooled procurement into the same warehouses. The National Health Insurance Scheme, created by the 2021 Act, expanded its contracted facilities from 13 to 69 in 2025 and is seeking mandatory contributions in 2026; its medicines benefit and any reimbursement list are not published in a form we could read. Tuberculosis incidence is 138 per 100,000, and the demand for sterile injectables is the general hospital formulary — antibiotics, anaesthetics, emergency and maternal-health medicines — rather than a single programme. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on The Gambia's list of recognised regulatory authorities? Not by name on any of the three lists. The Reliance Policy of November 2023 names the EMA, EU and EEA authorities, MHRA, US FDA, PMDA, Swissmedic, Health Canada, TGA, WHO prequalification, AVAREF, ECOWAS/WAHO and PIC/S, plus any authority at WHO maturity level 3 or above; CDSCO holds that level for vaccines only. The June 2025 reliance guideline works from the WHO-Listed Authorities list, and the June 2026 listing guideline names forty stringent-authority countries without India. An Indian product therefore uses the standard 180-day registration route. What does a Gambian registration application require? Under Registration Guideline MCA-GL-102: an MCA-format CTD, or a WAHO, WHO, EU or ICH CTD, in English, with one hard copy of Module 1 and the full dossier on USB; three commercial-pack samples with batch certificates of analysis; a manufacturing licence and GMP certificate; evidence of registration and marketing in the country of origin with a WHO-format CPP as applicable; a local representative registered in The Gambia for a non-resident holder; and a Gambia-resident pharmacovigilance person. The 2022 fees regulations put registration of an imported medicine at USD 300. How long does registration take and how long is it valid? The MCA acknowledges within two weeks, reviews a standard application within 180 days and an abridged one within 90 days, with the clock stopping on queries. The authorisation is valid for five years and can be renewed once for three years, after which a fresh application is needed; renewal must be filed at least 90 days before expiry. What is the pre-shipment inspection requirement for Indian medicines? Since June 2023, guidance MCA-G-113/04 has required every pharmaceutical consignment from India to carry a Clean Report of Inspection and Analysis issued through Quntrol Laboratories in Mumbai, covering a document check, physical inspection at loading, and sampling and testing at an MCA-approved laboratory. Injectables are analysed in about fifteen days, the certificate is valid for ninety days and the product must arrive with at least 60% shelf life. We could not verify how it is enforced in 2026; plan for it in full. How do we sell to the public sector in The Gambia? Through Central Medical Stores and the Directorate of National Pharmaceutical Services, which procure for public facilities under the Public Procurement Act 2022 via the GPPA portal, and through the Global Fund programmes for malaria, HIV and TB whose grants run to 2026 and 2027. Registration with the MCA comes first, and a local importer holding MCA importer and warehouse licences is the practical partner. The National Health Insurance Scheme is expanding but its medicines benefit was not published in a form we could read. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: September 2, 2026 TL;DR: Jamaica answers the question we always ask first — is there a list of regulators the country relies on, and is India on it — in a way no market in this series has quite matched: the regulation has no list, the procurement agency has one, and the regional reliance mechanism has another. The Food and Drugs Regulations of 1975 contain no reliance or abridged pathway at all; a new drug needs a certificate from the competent authority of the country of manufacture, five samples, a bioequivalence study for a generic, embassy-authenticated documents and a J$5,000 fee, and the Minister must respond within 120 days. In June 2025 the Minister announced a fast track for products already approved to United States, United Kingdom or European standards, but we found no implementing guideline or gazetted list and will not say whether one now exists. The National Health Fund's 2022 pharmaceutical tender, which supplies the public hospitals and Drug Serv pharmacies, accepts unregistered products only if registered by the Caribbean Regulatory System, the US FDA, Health Canada, the MHRA or the EMA, or WHO-prequalified; CDSCO is not on that list. The route for an Indian sterile injectable is therefore the ordinary Jamaican registration done well, and the commercial prize is a single public buyer that tenders internationally and lets manufacturers bid directly. Key Takeaways There is no reliance route in the regulation. Regulation 65 of the Food and Drugs Regulations 1975 requires a certificate from the competent authority of the country of manufacture or export, full quality and safety data, five finished-product samples with reference standards and, for generics, a bioequivalence study in at least twelve subjects. Regulation 68 obliges the Minister to say within 120 days whether the application is satisfactory. Documents must be authenticated by a Jamaican mission or, failing that, a British one. A named list exists, but at the procurement level. National Health Fund tender NHF-RX1/2022 accepts an item not registered in Jamaica only if it is registered by the Caribbean Regulatory System, the US FDA, Health Canada, the UK MHRA or the EMA, or is WHO-prequalified, and even then subject to Ministry approval. CDSCO is absent. Whether the next round repeats the clause is unknown; the safe assumption is that Jamaican registration is the ticket to the tender. The Caribbean Regulatory System is a recommendation, not a registration. CARPHA's 2020 guidance limits CRS to products holding a marketing authorisation from a reference authority or WHO prequalification; its reference list runs from ANMAT and ANVISA to the FDA, EMA, MHRA, PMDA and Swissmedic, and CDSCO is not on it. Member states are asked to decide within 60 days and may still demand a CPP, certificate of analysis and methods. The commercial gate is one buyer that tenders internationally. The NHF procures for state hospitals, health centres and 106 Drug Serv pharmacies; the 2023–2026 round awarded 61 contracts worth J$27 billion to 34 local and international suppliers, item by item on lowest evaluated price, with the distributor licence waived for manufacturers bidding directly. Out-of-pocket spending is 20.2% of health expenditure, so the State is the demand. Introduction: Why Jamaica Demands a Premium Injectable Manufacturer in Jamaica We open every market in this series by asking whether the country keeps a list of regulatory authorities whose approvals it will lean on, and whether India's CDSCO is among them. Jamaica gives three different answers depending on where you look, and the distinctions matter. In the law itself there is no list because there is no reliance route: the Food and Drugs Act of 1964 and the Food and Drugs Regulations of 1975 require every drug to be registered with the Ministry of Health before it is imported, manufactured or sold, and regulation 65 treats as a new drug anything not imported before August 1975 or new in its country of manufacture. The application must carry the formulation, route, dose, claims and contraindications, the potency, purity and safety testing, draft labels, finished-product and component samples, a certificate from the competent authority in the country of manufacture or export confirming the product is approved there, and a manufacturer's safety certificate. Regulation 68 then obliges the Minister to notify the applicant within 120 days whether the application is satisfactory. The Ministry's Pharmaceutical and Regulatory Affairs Department turns that into a practical checklist on its 2016 form: three copies of the summarised dossier, a clinical-pharmacology summary with a bioequivalence study in not fewer than twelve subjects for any generic, an original certificate of analysis on a recent batch with the method, five copies of the draft labels, five samples of the finished product with reference standards, an original WHO-format certificate of a pharmaceutical product, a list of countries where the product is approved or refused, and authentication of the documents by a Jamaican embassy or consulate or, where there is none, a British High Commission. The fee on that form is J$5,000 per presentation, and we do not know whether it has since been revised. Two conditions catch exporters out: products should have been on the market in the country of manufacture or export for at least a year before submission, life-threatening indications excepted, and where the innovator is not registered in Jamaica a generic is treated as a new drug. In June 2025 the Minister announced a fast track for products already approved to US, UK or European standards and acknowledged that 80% of dossiers are delayed for incompleteness. We found no implementing guideline or gazetted list of authorities, so whether a formal reliance list now exists is unknown in both directions — and for a premium injectable manufacturer in Jamaica the practical lesson is that a complete file, not a reliance argument, is what moves a registration. What Sets a World-Class Injectable Manufacturer in Jamaica Apart The dossier Jamaica asks for is not the CTD, and a supplier who simply ships a CTD will be returned. The form wants English, hard-bound and indexed copies of a summarised statement, and the department states that incomplete submissions are sent back. Within that structure the substance is familiar to any WHO-GMP manufacturer: full specifications and validated methods, stability data supporting the claimed shelf life in the Jamaican climate zone, and a certificate of analysis on a recent batch. The certificate of a pharmaceutical product is the pivot document — regulation 65(2)(g) requires it, and regulation 65(3) allows the Minister to accept an application without it only where detailed safety-test reports accompany the file. A GMP certificate does not appear on the registration checklist as we read it, because the CPP embeds GMP status, but the National Health Fund does require one for any unregistered reference-approved product it considers, so it belongs in the pack regardless. Once registered, importation runs on permits issued by the department, and the form asks for the name and address of a local representative where that differs from the applicant. We did not find a rule that the applicant must be a Jamaican-registered entity, and we did not read the Pharmacy Act's importer and wholesaler licensing provisions, so we neither assert nor deny that a local company is legally required; commercially, a Jamaican distributor is how the public tender is usually won, as the largest 2023 awards to LASCO Distributors, Cari-Med and Facey Commodity show. The registration's validity period and renewal cycle are not in the regulations as we read them, and the figures of twenty working days for a status approval and annual renewal appear only on consultancy websites, so we do not repeat them as fact. Neither Jamaica nor India is a PIC/S participating authority. Quality Systems Behind Every Injectable Supplied to Jamaica For a sterile injectable, Jamaica's requirements for potency, purity and stability testing translate into the same evidence a stringent inspector would want: media-fill records for the ISO Class 5 filling line, sterility and bacterial endotoxin testing by LAL, container-closure integrity, particulate matter, and HPLC or GC assay and impurity methods validated to ICH standards. Stability should be presented for the hot and humid zone Jamaica sits in, with ICH Q1A long-term and accelerated data rather than a temperate-zone extrapolation. Because the country-of-manufacture certificate is the anchor document, the CDSCO-issued WHO-format CPP must match the dossier exactly in strength, pack, manufacturing site and shelf life; a mismatch is the kind of small thing that costs a year. The regional layer deserves accuracy rather than enthusiasm. The Caribbean Regulatory System, hosted at CARPHA in Port of Spain since 2016 with PAHO and WHO, is described in its own guidance as a regional reliance mechanism that provides recommendations for market authorisation, verifying that a product is the same as one authorised by a reference authority or prequalified by the WHO. Its eligibility rule has no third route, and its reference-authority table — ANMAT, ANVISA, Health Canada, ISP, INVIMA, CECMED, COFEPRIS and the US FDA regionally, TGA, the EMA and EU authorities, MHRA, PMDA and Swissmedic beyond — does not include CDSCO. An Indian WHO-GMP product without WHO prequalification or a reference-authority authorisation cannot use CRS on the text as we read it; whether that table has been revised since November 2020 we do not know. And a CRS recommendation binds no one: national authorities are asked to decide within 60 days and may still require a CPP, certificate of analysis and methods. Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry. Why Farbe Firma is the Trusted Injectable Manufacturer in Jamaica for Global Buyers Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format and we know how to reshape them into the summarised, bound and indexed presentation Jamaica's form actually asks for, with the WHO-format CPP, certificate of analysis, five samples and reference standards, twelve-subject bioequivalence data where a generic requires it, and embassy authentication arranged in advance rather than discovered at submission. Our analytical package — HPLC, GC, LAL, Karl Fischer, ICH Q1A/Q1B stability — is written so that a 120-day review has nothing to send back, which in a system where the Minister has said most files are delayed for incompleteness is the single largest lever a supplier controls. The bilateral relationship is warm and the trade is real, without any regulatory shortcut attached. India's Ministry of External Affairs records bilateral trade of USD 116.73 million in 2023–24 and names pharmaceutical products first among India's exports to Jamaica; the Indian community of roughly five thousand is described as engaged primarily in pharmaceuticals and related businesses. The MEA brief lists cultural, research, aviation and foreign-service agreements but no pharmaceutical memorandum, mutual-recognition agreement or pharmacopoeia recognition, and a health memorandum reported as being finalised in 2019 we cannot confirm was signed. UN Comtrade puts India-reported HS 30 exports to Jamaica at USD 31.11 million in 2022, USD 32.05 million in 2023 and USD 30.36 million in 2024, with Jamaica reporting imports from India of USD 36.62 million in 2022 and about USD 33.80 million in 2024; we give both and average neither. Where the money is: Jamaica has 2.84 million people, gross national income per capita of USD 7,790 in 2025, current health expenditure of about USD 520 per person and 7.6% of GDP in 2023, and life expectancy of 71.6 years. Out-of-pocket spending was 20.2% of health expenditure in 2023, so the State is the buyer, and the State buys through one agency. The National Health Fund, which absorbed Health Corporation Limited's pharmaceutical warehouse in 2011, procures, stores and distributes for the public hospitals, health centres and 106 Drug Serv pharmacies against the Ministry's Vital, Essential and Necessary list, and processes about three million prescriptions a year. Its tenders are international competitive bidding on the GOJEP portal, open to bidders from all countries, awarded item by item on lowest evaluated price for 36-month contracts, with the distributor licence requirement waived for manufacturers bidding directly. The clinical hook is non-communicable disease: the national lifestyle survey reported one in three adults hypertensive and one in eight diabetic, which drives demand for the injectable antibiotics, anticoagulants, analgesics and emergency medicines a general hospital formulary carries. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is India on Jamaica's list of recognised regulatory authorities? It depends which list. The Food and Drugs Regulations of 1975 have no reliance route and therefore no list. The June 2025 ministerial announcement named United States, United Kingdom and European standards for a fast track, and we found no implementing guideline, so whether a formal list now exists is unknown in both directions. The National Health Fund's 2022 tender accepts unregistered items registered by the Caribbean Regulatory System, the US FDA, Health Canada, the MHRA or the EMA, or WHO-prequalified; CDSCO is not on it. Neither is CDSCO a CRS reference authority. What exactly does a Jamaican new-drug application require? Under regulation 65 and the department's 2016 checklist: three bound copies of a summarised dossier covering formulation, route, dose, claims and contraindications; potency, purity and stability testing; a clinical-pharmacology summary with a twelve-subject bioequivalence study for a generic; an original certificate of analysis on a recent batch with the method; five draft labels; five finished-product samples with reference standards; an original WHO-format CPP; a list of approvals and refusals abroad; authentication by a Jamaican or British mission; and a J$5,000 fee, which may since have been revised. Can Farbe Firma use the Caribbean Regulatory System to enter Jamaica? Not without WHO prequalification or a reference-authority marketing authorisation. CARPHA's 2020 guidance restricts CRS to products holding an authorisation from one of its listed reference authorities or WHO prequalification, and CDSCO is not listed. Even a CRS recommendation is non-binding: Jamaica may still require a CPP, certificate of analysis and methods, and the NHF accepts CRS status only subject to Ministry approval. How do we sell to the public sector in Jamaica? Through the National Health Fund's international competitive tenders on the GOJEP portal, which supply the state hospitals, health centres and Drug Serv pharmacies against the VEN list. Bids are open to all countries, awarded per item on lowest evaluated price for 36 months, and a manufacturer bidding directly need not hold a distributor licence, though new suppliers need two institutional testimonials and a sample per unregistered product. In practice the largest awards go to Jamaican distributors, so a local partner is the usual route. How long does registration take and how long is it valid? Regulation 68 requires the Minister to notify within 120 days whether the application is satisfactory, and the Minister has publicly acknowledged that 80% of dossiers are delayed for incompleteness, so completeness is the real timeline. We did not find a validity period or renewal cycle in the regulations as read; the annual-renewal and twenty-working-day figures circulating online come from consultancy sites and we do not repeat them as fact. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog